| 1. |
Kato T, Nakano Y, Hongo F, Katano H, Miyagawa T, Ueda K, Azuma H, Nozawa M, Hinata N, Hori J, Otoshi T, Shimizu N, Aizawa M, Osada S, Matsui A, Oya M, Eto M, Tomita Y, Shinohara N, Uemura H:, Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART)., Int J Urol, 31 (3): 265-272, 2024.03. |
| 2. |
Blas L, Shiota M, Tsukahara S, Nagakawa S, Matsumoto T, Eto M:, Adverse Events of Cabozantinib Plus Nivolumab Versus Ipilimumab Plus Nivolumab., Clin Genitourin Cancer, 22 (1): e122-e127.e1., 2024.02. |
| 3. |
Shiota M, Tsukahara S, Takamatsu D, Tanegashima T, Ueda S, Blas L, Goto S, Kobayashi S, Matsumoto T, Inokuchi J, Shioyama Y, Eto M:, Salvage robot-assisted radical prostatectomy after carbon ion radiotherapy to the prostate., Asian J Endosc Surg, 17 (1): e13279, 2024.01. |
| 4. |
Kiyozawa D, Kohashi K, Takamatsu D, Umekita S, Eto M, Kinjo M, Nishiyama K, Taguchi K, Oshiro Y, Kuboyama Y, Oda Y:, Comparative analyses of tumour immune microenvironment between collecting duct carcinoma and fumarate hydratase-deficient renal cell carcinoma., J Clin Pathol, 77 (2): 105-110, 2024.01. |
| 5. |
Shiota M, Terada N, Kimura T, Kitamura H, Kamoto T, Eto M; Japanese Urological Oncology Group (JUOG):, Differential cancer-specific survival with curative radiotherapy to the prostate for metastatic prostate cancer according to estimated survival by risk group., Int J Urol, 30 (12): 1197-1199, 2023.12. |
| 6. |
Shiota M, Tsukahara S, Ueda S, Mutaguchi J, Goto S, Kobayashi S, Matsumoto T, Blas L, Monji K, Inokuchi J, Eto M:, Improved urinary continence recovery after robot-assisted radical prostatectomy with lateral pelvic fascia preservation., J Robot Surg, 17 (6): 2721-2728, 2023.12. |
| 7. |
Ohba K, Monji K, Osawa T, Yamana K, Yasuda Y, Tanaka H, Nakagawa Y, Fukuyama T, Matsubara N, Uemura H, Sakai H, Eto M:, Comprehensive investigation of clinicopathological and immunological features to determine prognostic impact in metastatic renal cell carcinoma: The JEWEL study., Int J Urol, 30 (11): 977-984, 2023.11. |
| 8. |
Blas L, Shiota M, Matsumoto T, Hori Y, Nakamura M, Seki N, Kuroiwa K, Yokomizo A, Morokuma F, Kiyoshima K, Eto M:, Bone-modifying agents are protective for symptomatic skeletal events in Radium-223 treatment., Int J Urol, 30 (11): 1029-1034, 2023.11. |
| 9. |
Minami K, Osawa T, Kojima T, Hara T, Eto M, Takeuchi A, Nakai Y, Ueda K, Ozawa M, Uemura M, Ohba K, Tamura K, Shindo T, Nakagomi H, Takahashi A, Anai S, Yokomizo A, Morizane S, Kimura T, Shimazui T, Miyauchi Y, Mitsuzuka K, Hara H, Yoshimura K, Shiina H, Ito YM, Murai S, Nishiyama H, Shinohara N, Kitamura H; Japanese Urological Oncology Group:, Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment., Urol Oncol, 41 (11): 458.e9-458.e19, 2023.11. |
| 10. |
Shiota M, Ushijima M, Tsukahara S, Nagakawa S, Blas L, Takamatsu D, Kobayashi S, Matsumoto T, Inokuchi J, Eto M:, NR5A2/HSD3B1 pathway promotes cellular resistance to second-generation antiandrogen darolutamide., Drug Resist Updat, 70: 100990, 2023.09. |
| 11. |
Blas L, Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M; SNiP-RCC Investigators:, Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study., Int J Urol, 30 (9): 788-796, 2023.09. |
| 12. |
Kato T, Wang C, Masumori N, Yamasaki T, Matsumoto H, Baba M, Ito K, Kimura T, Kitamura H, Takahashi M, Hongo F, Hasine K, Eto M, Ikeda JI, Nonomura N, Shinohara N:, T1a Renal Cell Carcinoma With Metastasis: Japanese Society of Renal Cancer Retrospective Multi-institute Results., Anticancer Res, 43 (9): 4061-4065, 2023.09. |
| 13. |
Kashiwagi E, Shiota M, Inokuchi J, Tsukahara S, Imada K, Monji K, Goto S, Matsumoto T, Eto M:, Comparison of Testosterone Level of Seminal Vesicle Fluid in Patients With Prostate Cancer Versus Other Malignancies., Anticancer Res, 43 (9): 4249-4254, 2023.09. |
| 14. |
Rha SY, Choueiri TK, Matveev VB, Alyasova A, Hong SH, Gordoa TA, Gurney H, Bjarnason GA, Buchler T, Pedrazzoli P, Takagi T, Park SH, Lee JL, Perini RF, He CS, McKenzie JA, Eto M:, Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial., Int J Cancer, 153 (6): 1241-1250, 2023.09. |
| 15. |
Grünwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, Motzer R, Hutson TE, Méndez-Vidal MJ, Hong SH, Winquist E, Goh JC, Maroto P, Buchler T, Takagi T, Burgents JE, Perini R, He C, Okpara CE, McKenzie J, Choueiri TK:, Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms., Front Oncol, 13: 1223282, 2023.08. |
| 16. |
Yamaguchi T, Goya M, Higashijima K, Tobu S, Sato R, Tatarano S, Mukai S, Uemura KI, Tatsugami K, Tsubouchi K, Shida Y, Ishii T, Sakai H, Matsuoka H, Haga N, Eto M, Igawa T, Kamoto T, Enokida H, Shin T, Noguchi M, Fujimoto N, Saito S, Kamba T:, Real-world treatment outcomes of patients with penile cancer in the Kyushu-Okinawa area of Japan in the pre-guideline era., Jpn J Clin Oncol, 53 (9): 837-844, 2023.08. |
| 17. |
Oki E, Ota M, Nakanoko T, Tanaka Y, Toyota S, Hu Q, Nakaji Y, Nakanishi R, Ando K, Kimura Y, Hisamatsu Y, Mimori K, Takahashi Y, Morohashi H, Kanno T, Tadano K, Kawashima K, Takano H, Ebihara Y, Shiota M, Inokuchi J, Eto M, Yoshizumi T, Hakamada K, Hirano S, Mori M:, Telesurgery and telesurgical support using a double-surgeon cockpit system allowing manipulation from two locations., Surg Endosc, 37 (8): 6071-6078, 2023.08. |
| 18. |
Le Duff M, Michinov E, Bracq MS, Mukae N, Eto M, Descamps J, Hashizume M, Jannin P:, Virtual reality environments to train soft skills in medical and nursing education: a technical feasibility study between France and Japan., Int J Comput Assist Radiol Surg, 18 (8): 1355-1362, 2023.08. |
| 19. |
Grünwald V, Powles T, Kopyltsov E, Kozlov V, Alonso-Gordoa T, Eto M, Hutson T, Motzer R, Winquist E, Maroto P, Keam B, Procopio G, Wong S, Melichar B, Rolland F, Oya M, Rodriguez-Lopez K, Saito K, McKenzie J, Porta C:, Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study., Eur Urol Oncol, 6 (4): 437-446, 2023.08. |
| 20. |
Blas L, Shiota M, Tsukahara S, Goto S, Kinoshita F, Matsumoto T, Monji K, Kashiwagi E, Inokuchi J, Eto M:, Fusion-targeted biopsy significantly improves prostate cancer detection in biopsy-naïve men., Int J Urol, 30 (7): 600-604, 2023.07. |
| 21. |
Blas L, Shiota M, Tsukahara S, Nagakawa S, Matsumoto T, Eto M:, Adverse Events of Abiraterone Acetate vs Enzalutamide., Urol Pract, 10 (4): 361-370, 2023.07. |
| 22. |
Kinoshita Y, Izukura R, Kishimoto J, Kanaoka M, Fujita H, Ando K, Nagai S, Akiyoshi S, Tagawa T, Kubo M, Inokuchi J, Ohuchida K, Oki E, Tanaka K, Eto M, Yoshizumi T, Nakamura M, Chishaki A:, Reliability, validity, and responsiveness of the Japanese version of the EORTC QLQ-ELD14 in evaluating the health-related quality of life of elderly patients with cancer., J Cancer Res Clin Oncol, 149 (8): 4899-4914, 2023.07. |
| 23. |
Shiota M, Tatarano S, Kamoto T, Matsuyama H, Sakai H, Igawa T, Kamba T, Fujimoto N, Sekine Y, Kimura H, Narita S, Terada N, Momozawa Y, Akamatsu S, Habuchi T, Yokomizo A, Naito S, Eto M:, Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study., Endocr Relat Cancer, 30 (7): e230044, 2023.06. |
| 24. |
Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M; SNiP-RCC investigators:, Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial., Cancer Immunol Immunother, 72 (6): 1903-1915, 2023.06. |
| 25. |
Lee JL, Desai C, Park SH, Tsuchiya N, Su PJ, Chan TTW, Gurney H, Gao S, Wang J, Sandner R, di Pietro A, Eto M:, Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis., Urol Oncol, 41 (5): 256.e17-256.e25, 2023.05. |
| 26. |
Takamatsu D, Kiyozawa D, Kohashi K, Kinoshita F, Toda Y, Ishihara S, Eto M, Oda Y:, Prognostic impact of CD73/adenosine 2A receptor (A2AR) in renal cell carcinoma and immune microenvironmental status with sarcomatoid changes and rhabdoid features., Pathol Res Pract, 244: 154423, 2023.04. |
| 27. |
Lee K, Shiota M, Takamatsu D, Ushijima M, Blas L, Okabe A, Kajioka S, Goto S, Kinoshita F, Matsumoto T, Monji K, Kashiwagi E, Inokuchi J, Oda Y, Eto M:, Correlation between extended pelvic lymph node dissection and urinary incontinence at early phase after robot-assisted radical prostatectomy., Int J Urol, 30 (4): 340-346, 2023.04. |
| 28. |
Shiota M, Inoue R, Tashiro K, Kobayashi K, Horiyama S, Kanji H, Eto M, Egawa S, Haginaka J, Matsuyama H:, A Phase Ii Trial of Abiraterone With Dutasteride for Second-Generation Antiandrogen- And Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancer., J Clin Pharmacol, 63 (4): 445-454, 2023.04. |
| 29. |
Shiota M, Akamatsu S, Sekine Y, Kimura H, Narita S, Fujimoto N, Terada N, Blas L, Habuchi T, Kamoto T, Momozawa Y, Eto M:, Genetic variations predicting progression with docetaxel and novel androgen-receptor pathway inhibitors., Cancer Sci, 114 (4): 1625-1634, 2023.04. |
| 30. |
Choueiri TK, Eto M, Motzer R, De Giorgi U, Buchler T, Basappa NS, Méndez-Vidal MJ, Tjulandin S, Hoon Park S, Melichar B, Hutson T, Alemany C, McGregor B, Powles T, Grünwald V, Alekseev B, Rha SY, Kopyltsov E, Kapoor A, Alonso Gordoa T, Goh JC, Staehler M, Merchan JR, Xie R, Perini RF, Mody K, McKenzie J, Porta CG:, Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study., Lancet Oncol, 24 (3): 228-238, 2023.03. |
| 31. |
Eto M, Takagi T, Kimura G, Fukasawa S, Tamada S, Miura Y, Oya M, Sassa N, Anai S, Nozawa M, Sakai H, Perini R, Yusa W, Ikezawa H, Narita T, Tomita Y:, Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study., Cancer Med, 12 (6): 6902-6912, 2023.03. |
| 32. |
Kai K, Fujiwara T, Nagao Y, Oki E, Yoshizumi T, Eto M, Nakashima Y:, Evaluation of bone density and skeletal muscle mass after sleeve gastrectomy using computed tomography method., Bone Rep, 18: 101661, 2023.02. |
| 33. |
Kirisawa T, Shiota M, Kimura T, Edamura K, Miyake M, Morizane S, Yoshino T, Matsukawa A, Matsumoto R, Kasahara T, Nishiyama N, Eto M, Kitamura H, Nakamura E, Matsui Y; Japanese Urological Oncology Group:, Comparison of therapeutic features and oncologic outcome in patients with pN1 prostate cancer among robot-assisted, laparoscopic, or open radical prostatectomy., Int J Clin Oncol, 28 (2): 306-313, 2023.02. |
| 34. |
Tamada S, Nozawa M, Ohba K, Mizuno R, Takamoto A, Ohe C, Yoshimoto T, Nakagawa Y, Fukuyama T, Matsubara N, Kimura G, Tomita Y, Nonomura N, Eto M:, Prognostic value of PD-L1 expression in recurrent renal cell carcinoma after nephrectomy: a secondary analysis of the ARCHERY study., Int J Clin Oncol, 28 (2): 289-298, 2023.02. |
| 35. |
Matsumoto T, Hori Y, Shiota M, Blas L, Nakamura M, Seki N, Kuroiwa K, Yokomizo A, Morokuma F, Kiyoshima K, Eto M:, Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: A multi-institutional study., Int J Urol, 30 (2): 139-146, 2023.02. |
| 36. |
Blas L, Shiota M, Nagakawa S, Tsukahara S, Matsumoto T, Lee K, Monji K, Kashiwagi E, Inokuchi J, Eto M:, Validation of user-friendly models predicting extracapsular extension in prostate cancer patients., Asian J Urol, 10 (1): 81-88, 2023.01. |
| 37. |
Blas L, Shiota M, Takamatsu D, Kinoshita F, Matsumoto T, Lee K, Monji K, Kashiwagi E, Inokuchi J, Eto M:, Novel nomogram to predict biochemical recurrence-free survival after radical prostatectomy., World J Urol, 41 (1): 43-50, 2023.01. |
| 38. |
Takahashi Y, Narita S, Shiota M, Miura M, Kagaya H, Kashima S, Yamamoto R, Nara T, Huang M, Numakura K, Saito M, Eto M, Habuchi T:, Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate., Eur J Clin Pharmacol, 79 (1): 89-98, 2023.01. |
| 39. |
Osawa K, Bandara DSV, Nakadate R, Nagao Y, Akahoshi T, Eto M, Arata J:, 2.5-mm articulated endoluminal forceps using a compliant mechanism., Int J Comput Assist Radiol Surg, 18 (1): 1-8, 2023.01. |
| 40. |
Nonami A, Matsuo R, Funakoshi K, Nakayama T, Goto S, Iino T, Takaishi S, Mizuno S, Akashi K, Eto M:, Prospective study of adoptive activated αβT lymphocyte immunotherapy for refractory cancers: development and validation of a response scoring system., Cytotherapy, 25 (1): 76-81, 2023.01. |
| 41. |
Kato T, Matsubara N, Shiota M, Eto M, Osawa T, Abe T, Shinohara N, Yasumizu Y, Tanaka N, Oya M, Nishimoto K, Hayashi T, Nakayama M, Kojima T, Namikawa K, Fujisawa T, Okano S, Hida E, Nakamura Y, Bando H, Yoshino T, Nonomura N:, IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation., BMC Cancer, 22 (1): 1292, 2022.12. |
| 42. |
Kimura H, Mizuno K, Shiota M, Narita S, Terada N, Fujimoto N, Ogura K, Hatano S, Iwasaki Y, Hakozaki N, Ishitoya S, Sumiyoshi T, Goto T, Kobayashi T, Nakagawa H, Kamoto T, Eto M, Habuchi T, Ogawa O, Momozawa Y, Akamatsu S:, Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer., Br J Cancer, 127 (9): 1680-1690, 2022.11. |
| 43. |
Teoh JY, Ng CF, Eto M, Chiruvella M, Capitanio U, Esen T, Zeng G, Lechevallier E, Andonian S, de la Rosette J:, Radical nephroureterectomy for UTUC conferred survival benefits irrespective of age and comorbidities., World J Urol, 40 (11): 2657-2665, 2022.11. |
| 44. |
Kashiwagi E, Shiota M, Lee K, Monji K, Naganuma H, Matsumoto T, Takeuchi A, Inokuchi J, Eto M:, Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide., JMA J, 5 (4): 491-497, 2022.10. |
| 45. |
Kashiwagi E, Shiota M, Naganuma H, Monji K, Imada K, Lee K, Matsumoto T, Takeuchi A, Inokuchi J, Eto M:, Testosterone level in seminal vesicle fluid is a better indicator of erectile function than serum testosterone in patients with prostate cancer., Int J Urol, 29 (10): 1155-1162, 2022.10. |
| 46. |
Igami K, Uchiumi T, Shiota M, Ueda S, Tsukahara S, Akimoto M, Eto M, Kang D:, Extracellular vesicles expressing CEACAM proteins in the urine of bladder cancer patients., Cancer Sci, 113 (9): 3120-3133, 2022.09. |
| 47. |
Furukawa J, Hinata N, Teisima J, Takenaka A, Shiroki R, Kobayashi Y, Kanayama HO, Hattori K, Horie S, Tozawa K, Kato M, Ohyama C, Habuchi T, Kawamorita N, Eto M, Fujisawa M:, Robot-assisted partial nephrectomy with minimum follow-up of 5 years: A multi-center prospective study in Japan., Int J Urol, 29 (9): 1038-1045, 2022.09. |
| 48. |
Komori H, Blas L, Shiota M, Takamatsu D, Matsumoto T, Lee K, Monji K, Kashiwagi E, Inokuchi J, Eto M:, Impact of nerve sparing in robot-assisted radical prostatectomy on the risk of positive surgical margin and biochemical recurrence., Int J Urol, 29 (8): 824-829, 2022.08. |
| 49. |
Mizuta Y, Akahoshi T, Eto H, Hyodo F, Murata M, Tokuda K, Eto M, Yamaura K:, Noninvasive Diagnosis of the Mitochondrial Function of Doxorubicin-Induced Cardiomyopathy Using In Vivo Dynamic Nuclear Polarization-Magnetic Resonance Imaging., Antioxidants (Basel), 11 (8): 1454, 2022.07. |
| 50. |
Shiota M, Takamatsu D, Kimura T, Tashiro K, Matsui Y, Tomida R, Saito R, Tsutsumi M, Yokomizo A, Yamamoto Y, Edamura K, Miyake M, Morizane S, Yoshino T, Matsukawa A, Narita S, Matsumoto R, Kasahara T, Hashimoto K, Matsumoto H, Kato M, Akamatsu S, Joraku A, Kato M, Yamaguchi T, Saito T, Kaneko T, Takahashi A, Kato T, Sakamoto S, Enokida H, Kanno H, Terada N, Suekane S, Nishiyama N, Eto M, Kitamura H; Japanese Urological Oncology Group:, Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node-positive prostate cancer., Cancer Sci, 113 (7): 2386-2396, 2022.07. |
| 51. |
Mukai S, Sakamoto N, Kakinoki H, Shibuya T, Moriya R, Nishihara K, Noguchi M, Shin T, Fujimoto N, Igawa T, Ishii T, Haga N, Enokida H, Eto M, Kamba T, Sakai H, Saito S, Terada N, Kamoto T:, Serum IgG4 Concentration Is a Potential Predictive Biomarker in Glucocorticoid Treatment for Idiopathic Retroperitoneal Fibrosis., J Clin Med, 11 (12): 3538, 2022.06. |
| 52. |
Motzer R, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Bennett L, Wang J, Pan JJ, Saretsky TL, Perini RF, He CS, Mody K, Cella D:, Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study., Lancet Oncol, 23 (6): 768-780, 2022.06. |
| 53. |
Kusunoki M, Nakayama T, Nishie A, Yamashita Y, Kikuchi K, Eto M, Oda Y, Ishigami K:, A deep learning-based approach for the diagnosis of adrenal adenoma: a new trial using CT., Br J Radiol, 95 (1135): 20211066, 2022.06. |
| 54. |
Mutaguchi J, Morooka KI, Kobayashi S, Umehara A, Miyauchi S, Kinoshita F, Inokuchi J, Oda Y, Kurazume R, Eto M:, Artificial intelligence for segmentation of bladder tumor cystoscopic images performed by U-Net with dilated convolution., J Endourol, 36 (6): 827-834, 2022.06. |
| 55. |
小林 聡、中楯 龍、宮田信一、牟田口 淳、李 賢、門司恵介、柏木英志、武内在雄、塩田真己、猪口淳一、江藤正俊：, 医工連携で課題解決 - RAPNにおける超音波プローブアタッチメント開発 -., Jpn J Endourol Robot, 35 (1): 109-118, 2022.05. |
| 56. |
Tsukahara S, Shiota M, Takamatsu D, Nagakawa S, Matsumoto T, Kiyokoba R, Yagi M, Setoyama D, Noda N, Matsumoto S, Hayashi T, Contreras-Sanz A, Black PC, Inokuchi J, Kohashi K, Oda Y, Uchiumi T, Eto M, Kang D:, Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine., Sci Rep, 12 (1): 8535, 2022.05. |
| 57. |
Ushijima M, Shiota M, Matsumoto T, Kashiwagi E, Inokuchi J, Eto M:, An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer., Cancer Sci, 113 (5): 1731-1738, 2022.05. |
| 58. |
Blas L, Shiota M, Nagakawa S, Tsukahara S, Matsumoto T, Monji K, Kashiwagi E, Takeuchi A, Inokuchi J, Eto M:, Validation of models predicting lymph node involvement probability in patients with prostate cancer., Int J Urol, 29 (5): 428-434, 2022.05. |
| 59. |
Blas L, Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M:, External Validation of a Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Patients Receiving Post-Docetaxel Second-Line Chemotherapy., JMA J, 5 (2): 224-229, 2022.04. |
| 60. |
Yamada S, Shiota M, Blas L, Matsumoto T, Kashiwagi E, Takeuchi A, Inokuchi J, Shiga KI, Yokomizo A, Eto M:, Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer., Prostate Int, 10 (1): 50-55, 2022.03. |
| 61. |
Nakajima N, Miyajima A, Shinohara N, Obara W, Kondo T, Kimura G, Kume H, Fujimoto H, Sugiyama T, Nonomura N, Hongo F, Fukumori T, Takahashi M, Kanayama HO, Eto M:, Risk factors for recurrence after operation in patients with pT1a renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological Association., Jpn J Clin Oncol, 52 (3): 274-280, 2022.03. |
| 62. |
Chikamatsu S, Shiota M, Yamada S, Blas L, Matsumoto T, Kashiwagi E, Inokuchi J, Shiga KI, Yokomizo A, Eto M:, Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer., Prostate Int, 10 (1): 7-13, 2022.03. |
| 63. |
Kawazu M, Ueno T, Saeki K, Sax N, Togashi Y, Kaneseki T, Chida K, Kishigami F, Sato K, Kojima S, Otsuka M, Kawazoe A, Nishinakamura H, Maeda Y, Yamamoto Y, Yamashita K, Inoue S, Tanegashima T, Matsubara D, Tane K, Tanaka Y, Iinuma H, Hashiguchi Y, Hazama S, Khor SS, Tokunaga K, Tsuboi M, Niki T, Eto M, Shitara K, Torigoe T, Ishihara S, Aburatani H, Haeno H, Nishikawa H, Mano H:, HLA Class I analysis provides insight into the genetic and epigenetic background of immune evasion in colorectal cancer with high microsatellite instability., Gastroenterology, 162 (3): 799-812, 2022.03. |
| 64. |
Kobayashi M, Fujiyama N, Tanegashima T, Narita S, Yamamoto Y, Fujimoto N, Ueda S, Takeuchi A, Numakura K, Habuchi T, Matsuyama H, Eto M, Shiota M:, Effect of HLA genotype on intravesical recurrence after bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer., Cancer Immunol Immunother, 71 (3): 727-736, 2022.03. |
| 65. |
Kirisawa T, Shiota M, Kimura T, Edamura K, Miyake M, Morizane S, Yoshino T, Matsukawa A, Matsumoto R, Kasahara T, Nishiyama N, Eto M, Kitamura H, Nakamura E, Matsui Y; Japanese Urological Oncology Group:, Comparison of therapeutic features and oncologic outcome in patients with pN1 prostate cancer among robot-assisted, laparoscopic, or open radical prostatectomy., Int J Clin Oncol, 28 (2): 306-313, 2022.02. |
| 66. |
Tamada S, Nozawa M, Ohba K, Mizuno R, Takamoto A, Ohe C, Yoshimoto T, Nakagawa Y, Fukuyama T, Matsubara N, Kimura G, Tomita Y, Nonomura N, Eto M:, Prognostic value of PD-L1 expression in recurrent renal cell carcinoma after nephrectomy: a secondary analysis of the ARCHERY study., Int J Clin Oncol, 28 (2): 289-298, 2022.02. |
| 67. |
Tomita Y, Yamamoto Y, Tsuchiya N, Kanayama H, Eto M, Miyake H, Thomas P, Yoshida M, Koide Y, Umeyama Y, Pietro AD, Uemura H:, Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis., Int J Clin Oncol, 27 (2): 383-395, 2022.02. |
| 68. |
Shiota M, Fujimoto N, Sekino Y, Tsukahara S, Nagakawa S, Takamatsu D, Abe T, Kinoshita F, Ueda S, Ushijima M, Matsumoto T, Kashiwagi E, Inokuchi J, Uchiumi T, Oda Y, Eto M:, Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer., Andrologia, 54 (1): e14307, 2022.02. |
| 69. |
Harada M, Iida Y, Kotani H, Minami T, Komohara Y, Eto M, Yoshikawa K, Uemura H:, T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma., Cancer Immunol Immunother, 71 (2): 339-352, 2022.02. |
| 70. |
Blas L, Shiota M, Takamatsu D, Kinoshita F, Matsumoto T, Lee K, Monji K, Kashiwagi E, Inokuchi J, Eto M:, Novel nomogram to predict biochemical recurrence-free survival after radical prostatectomy., World J Urol, 41 (1): 43-50, 2022.01. |
| 71. |
Osawa K, Bandara DSV, Nakadate R, Nagao Y, Akahoshi T, Eto M, Arata J:, 2.5-mm articulated endoluminal forceps using a compliant mechanism., Int J Comput Assist Radiol Surg, 18 (1): 1-8, 2022.01. |
| 72. |
Matsumoto T, Shiota M, Yamada S, Blas L, Naganuma H, Lee K, Monji K, Kashiwagi E, Takeuchi A, Inokuchi J, Shiga KI, Yokomizo A, Eto M:, Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors., JMA J, 5 (1): 83-90, 2022.01. |
| 73. |
Shiota M, Blas L, Kobayashi S, Matsumoto T, Kashiwagi E, Takeuchi A, Inokuchi J, Shiga KI, Yokomizo A, Eto M:, Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer., Int J Urol, 29 (1): 26-32, 2022.01. |
| 74. |
Kobayashi H, Shiota M, Sato N, Kobayashi S, Matsumoto T, Monji K, Kashiwagi E, Takeuchi A, Inokuchi J, Shiga KI, Yokomizo A, Eto M:, Differential prognostic impact of complete blood count-related parameters by prior use of novel androgen receptor pathway inhibitors in docetaxel-treated castration-resistant prostate cancer patients., Anticancer Drugs, 33 (1): e541-e547, 2022.01. |
| 75. |
Takeuchi Y, Tanegashima T, Sato E, Irie T, Sai A, Itahashi K, Kumagai S, Tada Y, Togashi Y, Koyama S, Akbay EA, Karasaki T, Kataoka K, Funaki S, Shintani Y, Nagatomo I, Kida H, Ishii G, Miyoshi T, Aokage K, Kakimi K, Ogawa S, Okumura M, Eto M, Kumanogoh A, Tsuboi M, Nishikawa H:, Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape., Sci Immunol, 6 (65): eabc6424, 2021.11. |
| 76. |
Blas L, Ieiri K, Shiota M, Nagakawa S, Tsukahara S, Matsumoto T, Kashiwagi E, Takeuchi A, Inokuchi J, Shiga KI, Yokomizo A, Eto M:, Prognostic Value of Lower Tract Urinary Symptoms in Clinically Regional Lymph Node-positive Prostate Cancer., Anticancer Res, 41 (11): 5593-5598, 2021.11. |
| 77. |
Mizuno K, Sumiyoshi T, Okegawa T, Terada N, Ishitoya S, Miyazaki Y, Kojima T, Katayama H, Fujimoto N, Hatakeyama S, Shiota M, Yoshimura K, Matsui Y, Narita S, Matsumoto H, Kurahashi R, Kanno H, Ito K, Kimura H, Kamiyama Y, Sunada T, Goto T, Kobayashi T, Yamada H, Tsuchiya N, Kamba T, Matsuyama H, Habuchi T, Eto M, Ohyama C, Ito A, Nishiyama H, Okuno H, Kamoto T, Fujimoto A, Ogawa O, Akamatsu S:, Clinical Impact of Detecting Low-Frequency Variants in Cell-Free DNA on Treatment of Castration-Resistant Prostate Cancer., Clin Cancer Res, 27 (22): 6164-6173, 2021.11. |
| 78. |
Nagakawa S, Shiota M, Fujimoto N, Yamamoto Y, Blas L, Tsukahara S, Matsumoto T, Kashiwagi E, Takeuchi A, Inokuchi J, Uchiumi T, Matsuyama H, Eto M:, The impact of single-nucleotide polymorphisms on intravesical recurrence after bacillus Calmette-Guérin therapy for non-muscle invasive bladder cancer in a genome-wide association study., Urol Oncol, 39 (10): 733.e17-733.e24, 2021.10. |
| 79. |
Tobu S, Udo K, Nishihara K, Miyajima S, Ando T, Onizuka C, Itesako T, Ashikari A, Hakariya T, Igawa T, Tanaka M, Shin T, Kamoto T, Nakagawa M, Saito S, Sakai H, Eto M, Kamba T, Fujimoto N, Noguchi M:, Surveillance of urachal abscess in the Kyushu-Okinawa area of Japan., Int J Urol, 28 (10): 1008-1011, 2021.10. |
| 80. |
Shiota M, Terada N, Kitamura H, Kojima T, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Sugimoto M, Mizowaki T, Kamoto T, Nishiyama H, Eto M; Japanese Urological Oncology Group:, Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer., Cancer Sci, 112 (9): 3616-3626, 2021.09. |
| 81. |
Chikamatsu S, Shiota M, Onozawa M, Hinotsu S, Kitagawa Y, Sakamoto S, Kawai T, Eto M, Kume H, Akaza H; Japan Study Group of Prostate Cancer (J-CaP):, Dynamics of conditional survival and risk factors in androgen deprivation therapy for prostate cancer using a multi-institutional Japan-wide database., Int J Urol, 28 (9): 927-935, 2021.09. |
| 82. |
Goto S, Sakoda Y, Adachi K, Sekido Y, Yano S, Eto M, Tamada K:, Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models., Cancer Immunol Immunother, 70 (9): 2503-2515, 2021.09. |
| 83. |
Kawano T, Tachibana Y, Inokuchi J, Kang JH, Murata M, Eto M:, Identification of Activated Protein Kinase Cα (PKCα) in the Urine of Orthotopic Bladder Cancer Xenograft Model as a Potential Biomarker for the Diagnosis of Bladder Cancer., Int J Mol Sci, 22 (17): 9276, 2021.08. |
| 84. |
Morisaki T, Morisaki T, Kubo M, Onishi H, Hirano T, Morisaki S, Eto M, Monji K, Takeuchi A, Nakagawa S, Tanaka H, Koya N, Umebayashi M, Tsujimura K, Yew PY, Yoshimura S, Kiyotani K, Nakamura Y:, Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis., Anticancer Res, 41 (8): 4101-4115, 2021.08. |
| 85. |
Blas L, Shiota M, Yamada S, Ieiri K, Nagakawa S, Tsukahara S, Matsumoto T, Kashiwagi E, Takeuchi A, Inokuchi J, Shiga KI, Yokomizo A, Eto M:, Lactate Dehydrogenase Is a Serum Prognostic Factor in Clinically Regional Lymph Node-positive Prostate Cancer., Anticancer Res, 41 (8): 3885-3889, 2021.08. |
| 86. |
Blas L, Onozawa M, Shiota M, Hinotsu S, Sakamoto S, Kitagawa Y, Kawai T, Eto M, Kume H, Akaza H; Japan Study Group of Prostate Cancer (J-CaP):, Long-term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old., Cancer Sci, 112 (8): 3074-3082, 2021.08. |
| 87. |
Iwamoto C, Ohuchida K, Shinkawa T, Okuda S, Otsubo Y, Okumura T, Sagara A, Koikawa K, Ando Y, Shindo K, Ikenaga N, Nakata K, Moriyama T, Miyasaka Y, Ohtsuka T, Eto M, Akashi K, Nakamura M:, Bone marrow-derived macrophages converted into cancer-associated fibroblast-like cells promote pancreatic cancer progression., Cancer Lett, 512: 15-27, 2021.08. |
| 88. |
Shiota M, Akamatsu S, Narita S, Sumiyoshi T, Fujiwara M, Uchiumi T, Ogawa O, Habuchi T, Eto M:, The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer., Pharmacogenomics J, 21 (4): 440-445, 2021.08. |
| 89. |
Koura M, Shiota M, Ueda S, Matsumoto T, Kobayashi S, Monji K, Kashiwagi E, Takeuchi A, Inokuchi J, Shiga KI, Yokomizo A, Eto M:, Prognostic impact of prior local therapy in castration-resistant prostate cancer., Jpn J Clin Oncol, 51 (7): 1142-1148, 2021.07. |
| 90. |
Matsumoto T, Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M:, Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study., Prostate Int, 9 (2): 96-100, 2021.06. |
| 91. |
Kiyozawa D, Kohashi K, Takamatsu D, Yamamoto T, Eto M, Iwasaki T, Motoshita J, Shimokama T, Kinjo M, Oshiro Y, Yonemasu H, Oda Y:, Morphological, immunohistochemical, and genomic analyses of papillary renal neoplasm with reverse polarity., Hum Pathol, 112: 48-58, 2021.06. |
| 92. |
Machidori A, Shiota M, Kobayashi S, Matsumoto T, Monji K, Kashiwagi E, Takeuchi A, Takahashi R, Inokuchi J, Eto M:, Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitors., Urol Oncol, 39 (6): 365.e1-365.e7, 2021.06. |
| 93. |
Kobayashi S, Mutaguchi J, Kashiwagi E, Takeuchi A, Shiota M, Inokuchi J, Eto M:, Clinical advantages of robot-assisted partial nephrectomy versus laparoscopic partial nephrectomy in terms of global and split renal functions: A propensity score-matched comparative analysis., Int J Urol, 28 (6): 630-636, 2021.06. |
| 94. |
Nakai Y, Takeuchi A, Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Minami K, Ueda K, Ozawa M, Uemura M, Miyauchi Y, Ohba K, Kashiwagi A, Murakami M, Sazuka T, Yasumoto H, Morizane S, Kawasaki Y, Morooka D, Shimazui T, Yamamoto Y, Nakagomi H, Tomida R, Ito YM, Murai S, Kitamura H, Nishiyama H, Shinohara N; Japanese Urological Oncology Group., Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma., J Geriatr Oncol, 12 (5): 834-837, 2021.06. |
| 95. |
Shiota M, Fujimoto N, Matsumoto T, Tsukahara S, Nagakawa S, Ueda S, Ushijima M, Kashiwagi E, Takeuchi A, Inokuchi J, Uchiumi T, Eto M:, Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer., Front Oncol, 11: 697955, 2021.05. |
| 96. |
Shiota M, Sumikawa R, Onozawa M, Hinotsu S, Kitagawa Y, Sakamoto S, Kawai T, Eto M, Kume H, Akaza H; Japan Study Group of Prostate Cancer (J-CaP):, Regional and facility disparities in androgen deprivation therapy for prostate cancer from a multi-institutional Japan-wide database., Int J Urol, 28 (5): 584-591, 2021.05. |
| 97. |
Quinn DI, Ng CF, Grande E, Kwon TG, Linke R, Lee JL, Rosbrook B, Thakur MN, Eto M, Gross-Goupil M:, ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups., ESMO Open, 6 (3): 100-105, 2021.04. |
| 98. |
Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Mizowaki T, Kamoto T, Kojima T, Kitamura H, Sugimoto M, Nishiyama H, Eto M, Urological Oncology Group Juog J:, Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients., Cancer Sci, 112 (4): 1524-1533, 2021.04. |
| 99. |
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators:, Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma., N Engl J Med, 384 (14): 1289-1300, 2021.04. |
| 100. |
Hinata N, Shiroki R, Tanabe K, Eto M, Takenaka A, Kawakita M, Hara I, Hongo F, Ibuki N, Nasu Y, Teishima J, Kawai N, Kawauchi A, Kondo T, Kawamorita N, Oyama C, Horie S, Shimbo M, Kato M, Kanayama H, Koito Y, Fujisawa M; Japanese Society of Endourology:, Robot-assisted partial nephrectomy versus standard laparoscopic partial nephrectomy for renal hilar tumor: A prospective multi-institutional study., Int J Urol, 28 (4): 382-389, 2021.04. |
| 101. |
Fujimoto N, Shiota M, Matsukawa T, Minato A, Tomisaki I, Ohnishi R, Eto M:, Three-month Prostate-specific Antigen Level After Androgen Deprivation Therapy Predicts Survival in Patients With Metastatic Castration-sensitive Prostate Cancer., In Vivo, 35 (2): 1101-1108, 2021.03. |
| 102. |
Yamashita T, Shiota M, Machidori A, Kobayashi S, Matsumoto T, Monji K, Kashiwagi E, Takeuchi A, Takahashi R, Inokuchi J, Shiga KI, Yokomizo A, Eto M:, Efficacy and Safety of 4-Weekly Docetaxel for Castration-Resistant Prostate Cancer., Cancer Invest, 39 (3): 251-256, 2022.06. |
| 103. |
Naganuma H, Miike K, Ohmori T, Tanigawa S, Ichikawa T, Yamane M, Eto M, Niwa H, Kobayashi A, Nishinakamura R:, Molecular detection of maturation stages in the developing kidney., Dev Biol, 470: 62-73, 2021.02. |
| 104. |
Shiota M, Narita S, Habuchi T, Eto M:, Validated prognostic significance of YB-1 genetic variation in metastatic prostate cancer., Pharmacogenomics J, 21 (1): 102-105, 2021.02. |
| 105. |
Takahashi R, Takei M, Namitome R, Yamaguchi O, Eto M:, Symptoms and noninvasive test parameters that clinically differentiate detrusor underactivity from bladder outlet obstruction without a pressure-flow-based diagnosis in men with lower urinary tract symptoms., Neurourol Urodyn, 40 (1): 303-309, 2022.01. |
| 106. |
Matsumoto T, Shiota M, Uchiumi T, Ueda S, Tsukahara S, Toshima T, Matsumoto S, Noda N, Eto M, Kang D:, Genomic characteristics revealed by targeted exon sequencing of testicular germ cell tumors in Japanese men., Int J Urol, 28 (1): 40-46, 2021.01. |
| 107. |
Shiota M, Sekino Y, Tsukahara S, Abe T, Kinoshita F, Imada K, Ueda S, Ushijima M, Nagakawa S, Matsumoto T, Kashiwagi E, Takeuchi A, Inokuchi J, Uchiumi T, Oda Y, Eto M:, Gene amplification of YB-1 in castration-resistant prostate cancer in association with aberrant androgen receptor expression., Cancer Sci, 112 (1): 323–330, 2021.01. |
| 108. |
Matsukane R, Watanabe H, Minami H, Hata K, Suetsugu K, Tsuji T, Masuda S, Okamoto I, Nakagawa T, Ito T, Eto M, Mori M, Nakanishi Y, Egashira N:, Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events., Sci Rep, 11 (1): 1324, 2021.01. |
| 109. |
Nakai Y, Takeuchi A, Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Minami K, Ueda K, Ozawa M, Uemura M, Miyauchi Y, Ohba K, Kashiwagi A, Murakami M, Sazuka T, Yasumoto H, Morizane S, Kawasaki Y, Morooka D, Shimazui T, Yamamoto Y, Nakagomi H, Tomida R, Ito YM, Murai S, Kitamura H, Nishiyama H, Shinohara N; Japanese Urological Oncology Group., Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma., J Geriatr Oncol, S1879-4068 (20): 30534-30538, 2020.12. |
| 110. |
Masuda T, Nonami A, Tanaka F, Ando Y, Eto M, Mimori K:, A case of a patient receiving combination therapy with paclitaxel plus bevacizumab and adoptive activated αβ T-cell immunotherapy in advanced breast cancer., Breast J, 26 (12): 2420-2423, 2020.12. |
| 111. |
Shiota M, Machidori A, Abe T, Monji K, Kashiwagi E, Takeuchi A, Takahashi R, Inokuchi J, Yokomizo A, Naito S, Eto M:, Impact of antiandrogen withdrawal syndrome in castration-resistant prostate cancer patients treated with abiraterone or enzalutamide., Int J Urol, 27 (12): 1109-1115, 2020.12. |
| 112. |
Ieiri K, Shiota M, Kashiwagi E, Takeuchi A, Takahashi R, Inokuchi J, Iwai H, Shiga KI, Yokomizo A, Yoshitake T, Shioyama Y, Ishigami K, Terashima H, Eto M:, The prognosis and the impact of radiotherapy in clinically regional lymph node-positive prostate cancer: Which patients are candidates for local therapy with radiation?, Urol Oncol, 38 (12): 931.e1-931.e7, 2020.12. |
| 113. |
Tohi Y, Kato T, Matsumoto R, Shinohara N, Shiga K, Yokomizo A, Nakamura M, Kume H, Mitsuzuka K, Sasaki H, Egawa S, Matsumura M, Hashine K, Inokuchi J, Eto M, Baba H, Ichikawa T, Kinoshita H, Matsuda T, Kakehi Y, Sugimoto M:, The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study., Int J Clin Oncol, 25 (12): 2107-2114, 2020.12. |
| 114. |
Mizuta Y, Akahoshi T, Guo J, Zhang S, Narahara S, Kawano T, Murata M, Tokuda K, Eto M, Hashizume M, Yamaura K:, Exosomes from adipose tissue-derived mesenchymal stem cells ameliorate histone-induced acute lung injury by activating the PI3K/Akt pathway in endothelial cells., Stem Cell Res Ther, 11 (1): 508, 2020.11. |
| 115. |
Sato N, Shiota M, Shiga KI, Kashiwagi E, Takeuchi A, Inokuchi J, Yokomizo A, Naito S, Eto M:, Effect of Smoking on Oncological Outcome among Prostate Cancer Patients after Radical Prostatectomy with Neoadjuvant Hormonal Therapy., Cancer Invest, 38 (10): 559-564, 2020.11. |
| 116. |
Shiota M, Endo S, Fujimoto N, Tsukahara S, Ushijima M, Kashiwagi E, Takeuchi A, Inokuchi J, Uchiumi T, Eto M:, Polymorphisms in androgen metabolism genes with serum testosterone levels and prognosis in androgen-deprivation therapy., Urol Oncol, 38 (11): 849.e11-849.e18, 2020.11. |
| 117. |
de la Rosette J, Laguna P, Álvarez-Maestro M, Eto M, Mochtar CA, Albayrak S, Mendoza-Valdes A, Ong TA, Khadgi S, Al-Terki A, Bolton D, Gomez R, Klotz L, Kulkarni S, Tanguay S, Gravas S; Société Internationale d’Urologie Board of Directors:, Cross-continental comparison of safety and protection measures amongst urologists during COVID-19., Int J Urol, 27 (11): 981-989, 2020.11. |
| 118. |
Kinoshita F, Kohashi K, Sugimoto M, Takamatsu D, Kiyozawa D, Eto M, Oda Y:, The SWI/SNF Chromatin-Remodeling Complex Status in Renal Cell Carcinomas With Sarcomatoid or Rhabdoid Features., Virchows Arch, 477 (5): 651-660, 2020.11. |
| 119. |
Ito K, Mikami S, Kuroda N, Nagashima Y, Tatsugami K, Masumori N, Kondo T, Takagi T, Nakanishi S, Eto M, Kamba T, Tomita Y, Matsuyama H, Tsushima T, Nakazawa H, Oya M, Kimura G, Shinohara N, Asano T:, Difficulty in differential diagnosis for renal cancer with microscopic papillary architecture: overlapped pathological features among papillary renal cell carcinoma (RCC), mutinous tubular and spindle cell carcinoma, and unclassified RCC. Lessons from a Japanese multicenter study., Jpn J Clin Oncol, 50 (11): 1313-1320, 2020.10. |
| 120. |
Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, Ohyama C, Ogawa O, Kikuchi E, Kitamura H, Shinohara N, Takahashi S, Tsuzuki T, Nakagawa M, Narumi Y, Nishiyama H, Habuchi T, Hinotsu S, Fujii Y, Fujimoto K, Fujimoto H, Mizowaki T, Matsuyama H:, Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: Summary of the revision., Int J Urol, 27 (9): 702-709, 2020.09. |
| 121. |
Itsumi M, Shiota M, Sekino Y, Ushijima M, Kashiwagi E, Takeuchi A, Inokuchi J, Kajioka S, Uchiumi T, Eto M:, High-throughput Screen Identifies 5-HT Receptor as a Modulator of AR and a Therapeutic Target for Prostate Cancer., Prostate, 80 (11): 885-894, 2020.08. |
| 122. |
Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Takeuchi A, Minami K, Nakai Y, Ueda K, Ozawa M, Uemura M, Miyauchi Y, Ohba K, Suzuki T, Anai S, Shindo T, Kusakabe N, Tamura K, Komiyama M, Goto T, Yokomizo A, Kohei N, Kashiwagi A, Murakami M, Sazuka T, Yasumoto H, Iwamoto H, Mitsuzuka K, Morooka D, Shimazui T, Yamamoto Y, Ikeshiro S, Nakagomi H, Morita K, Tomida R, Mochizuki T, Inoue T, Kitamura H, Yamada S, Ito YM, Murai S, Nishiyama H, Shinohara N; Japanese Urological Oncology Group, Fukuda H:, Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma., Cancer Sci, 111 (7): 2460–2471, 2020.07. |
| 123. |
Shiota M, Fujimoto N, Yamamoto Y, Takeuchi A, Tatsugami K, Uchiumi T, Matsuyama H, Eto M:, Genome-wide association study of genetic variations associated with treatment failure after intravesical bacillus Calmette-Guérin therapy for non-muscle invasive bladder cancer., Cancer Immunol Immunother, 69 (7): 1155-1163, 2020.07. |
| 124. |
Kobayashi S, Cho B, Mutaguchi J, Inokuchi J, Tatsugami K, Hashizume M, Eto M:, Surgical Navigation Improves Renal Parenchyma Volume Preservation in Robot-Assisted Partial Nephrectomy: A Propensity Score-matched Comparative Analysis., J Urol, 204 (1): 149-156, 2020.07. |
| 125. |
Takahashi R, Kimoto Y, Maki T, Eto M:, Postinjury Bladder Overdistension Deteriorates the Lower Urinary Tract's Storage Function in Patients with Spinal Cord Injury., Urol Int, 104 (7-8):604-609, 2020.06. |
| 126. |
Kashiwagi E, Abe T, Kinoshita F, Ushijima M, Masaoka H, Shiota M, Netto GJ, Eto M, Miyamoto H:, The role of adipocytokines and their receptors in bladder cancer: expression of adiponectin or leptin is an independent prognosticator., Am J Transl Res, 12(6): 3033–3045, 2020.06. |
| 127. |
Takahashi R, Sumino Y, Miyazato M, Nishii H, Oshiro T, Mimata H, Saito S, Yoshida M, Eto M:, Tadalafil Improves Nocturia and Nocturia-Related Quality of Life in Patients With Benign Prostatic Hyperplasia (KYU-PRO Study)., Urol Int, 104(7-8): 587-593, 2020.06. |
| 128. |
Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, Ohyama C, Ogawa O, Kikuchi E, Kitamura H, Shinohara N, Takahashi S, Tsuzuki T, Nakagawa M, Narumi Y, Nishiyama H, Habuchi T, Hinotsu S, Fujii Y, Fujimoto K, Fujimoto H, Mizowaki T, Matsuyama H:, Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: Revision working position paper., Int J Urol, 27 (5): 362-368, 2020.05. |
| 129. |
Noguchi M, Arai G, Egawa S, Ohyama C, Naito S, Matsumoto K, Uemura H, Nakagawa M, Nasu Y, Eto M, Suekane S, Sasada T, Shichijo S, Yamada A, Kakuma T, Itoh K:, Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial., Cancer Immunol Immunother, 69 (5): 847-857, 2020.05. |
| 130. |
Kiyozawa D, Takamatsu D, Kohashi K, Kinoshita F, Ishihara S, Toda Y, Eto M, Oda Y:, Programmed Death Ligand 1/indoleamine 2,3-dioxygenase 1 Expression and Tumor-Infiltrating Lymphocyte Status in Renal Cell Carcinoma With Sarcomatoid Changes and Rhabdoid Features., Hum Pathol, 101: 31-39, 2020.04. |
| 131. |
Shiota M, Onozawa M, Hinotsu S, Eto M, Naito S, Akaza H; Japan Study Group of Prostate Cancer (J-CaP):, Family history in primary hormone therapy for prostate cancer: Analysis from a community-based multi-institutional Japan-wide database., Int J Urol, 27 (4): 313-318, 2020.04. |
| 132. |
Namitome R, Takei M, Takahashi R, Kikutake C, Yokomizo A, Yamaguchi O, Eto M:, A Prediction Model of Detrusor Underactivity Based on Symptoms and Noninvasive Test Parameters in Men with Lower Urinary Tract Symptoms: An Analysis in a Large Group of Patients Undergoing Pressure-flow Studies., J Urol, 203 (4): 779-785, 2020.04. |
| 133. |
Kashiwagi E, Imada K, Abe T, Kinoshita F, Monji K, Shiota M, Takeuchi A, Inokuchi J, Tatsugami K, Eto M:, Thick perirenal fat predicts the growth pattern of renal cell carcinoma., Kidney Cancer, 4 (1): 41-48, 2020.03. |
| 134. |
Kashiwagi E, Shiota M, Masaoka H, Imada K, Monji K, Takeuchi A, Inokuchi J, Tatsugami K, Eto M:, Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer., Prostate Int, 8 (1) :22-26, 2020.03. |
| 135. |
Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M:, Prognostic significance of lactate dehydrogenase in cabazitaxel chemotherapy for castration-resistant prostate cancer: a multi-institutional study., Anticancer Drugs, 31 (3): 298-303, 2020.03. |
| 136. |
Uemura M, Tomita Y, Miyake H, Hatakeyama S, Kanayama HO, Numakura K, Takagi T, Kato T, Eto M, Obara W, Uemura H, Choueiri TK, Motzer RJ, Fujii Y, Kamei Y, Umeyama Y, di Pietro A, Oya M:, Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101., Cancer Sci, 111 (3): 907–923, 2020.03. |
| 137. |
Mitsui R, Lee K, Uchiyama A, Hayakawa S, Kinoshita F, Kajioka S, Eto M, Hashitani H:, Contractile elements and their sympathetic regulations in the pig urinary bladder: a species and regional comparative study., Cell Tissue Res, 379 (2): 373-387, 2020.02. |
| 138. |
Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M:, Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel., Anticancer Res, 40 (1): 335-339, 2020.01. |
| 139. |
Tanaka M, Irie S, Nakagawa K, Nishimatsu H, Inokuchi J, Eto M:, Nonischemic or Ischemic Laparoscopic Partial Nephrectomy Using a Newly Developed Hybrid Energy Device in a Porcine Model., J Endourol, 34 (1): 82-87, 2020.01. |
| 140. |
Hirata Y, Shiota M, Kobayashi T, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Eto M:, Prognostic significance of diabetes mellitus and dyslipidemia in men receiving androgen-deprivation therapy for metastatic prostate cancer., Prostate Int, 7 (4): 166-170, 2019.12. |
| 141. |
Kume H, Homma Y, Shinohara N, Obara W, Kondo T, Kimura G, Fujimoto H, Nonomura N, Hongo F, Sugiyama T, Takahashi M, Kanayama HO, Fukumori T, Eto M:, Corrigendum to: Perinephric invasion as a prognostic factor in non-metastatic renal cell carcinoma: analysis of a nation-wide registry program., Jpn J Clin Oncol, 49 (11): 1067, 2020.12. |
| 142. |
Kuroiwa K, Inokuchi J, Nishiyama H, Kojima T, Kakehi Y, Sugimoto M, Tanigawa T, Fujimoto H, Gotoh M, Masumori N, Ogawa O, Eto M, Ohyama C, Yokomizo A, Matsuyama H, Ichikawa T, Mizusawa J, Eba J, Naito S; Urologic Oncology Study Group of the Japan Clinical Oncology Group (JCOG):, Impact of Previous, Simultaneous or Subsequent Bladder Cancer on Prognosis after Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma., J Urol, 202 (6): 1127-1135, 2019.12. |
| 143. |
Shiota M, Kobayashi T, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Eto M:, Prognostic significance of antihypertensive agents in men with castration-resistant prostate cancer., Urol Oncol, 37 (11): 813.e21-813.e26, 2019.11. |
| 144. |
Kashiwagi E, Imada K, Monji K, Takeuchi A, Shiota M, Inokuchi J, Tatsugami K, Eto M:, Psoas muscle volume is correlated with sexual activity and erectile dysfunction among patients with localised prostate cancer., Andrologia, 51 (9): e13354, 2019.10. |
| 145. |
Ohyama C, Kojima T, Kondo T, Naya Y, Inoue T, Tomita Y, Eto M, Hisasue S, Uemura H, Obara W, Kikuchi E, Sharma P, Galsky MD, Siefker-Radtke A, Grossfeld G, Collette S, Gooden K, Kimura G:, Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses., Int J Clin Oncol, 24 (9): 1089-1098, 2019.09. |
| 146. |
Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M:, Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study., Cancer Chemother Pharmacol, 84 (3): 561-566, 2019.09. |
| 147. |
Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M:, Therapeutic Outcome of >10 Cycles of Cabazitaxel for Castration-resistant Prostate Cancer: A Multi-institutional Study., Anticancer Res, 39 (8): 4411-4414, 2019.08. |
| 148. |
Akitake M, Yamaguchi A, Shiota M, Imada K, Tatsugami K, Yokomizo A, Naito S, Eto M:, Predictive Factors for Residual Cancer in Second Transurethral Resection for Non-muscle-invasive Bladder Cancer., Anticancer Res, 39 (8): 4325-4328, 2019.08. |
| 149. |
Kobayashi S, Cho B, Huaulmé A, Tatsugami K, Honda H, Jannin P, Hashizumea M, Eto M:, Assessment of surgical skills by using surgical navigation in robot-assisted partial nephrectomy., Int J Comput Assist Radiol Surg, 14 (8): 1449-1459, 2019.08. |
| 150. |
Tanegashima T, Togashi Y, Azuma K, Kawahara A, Ideguchi K, Sugiyama D, Kinoshita F, Akiba J, Kashiwagi E, Takeuchi A, Irie T, Tatsugami K, Hoshino T, Eto M, Nishikawa H:, Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity., Clin Cancer Res, 25 (15): 4808-4819, 2019.08. |
| 151. |
Baba M, Furuya M, Motoshima T, Lang M, Funasaki S, Ma W, Sun HW, Hasumi H, Huang Y, Kato I, Kadomatsu T, Satou Y, Morris N, Karim BO, Ileva L, Kalen JD, Wilan Krisna LA, Hasumi Y, Sugiyama A, Kurahashi R, Nishimoto K, Oyama M, Nagashima Y, Kuroda N, Araki K, Eto M, Yao M, Kamba T, Suda T, Oike Y, Schmidt LS, Linehan WM:, TFE3 Xp11.2 translocation renal cell carcinoma mouse model reveals novel therapeutic targets and identifies GPNMB as a diagnostic marker for human disease., Mol Cancer Res, 17 (8): 1613-1626, 2019.08. |
| 152. |
Kume H, Homma Y, Shinohara N, Obara W, Kondo T, Kimura G, Fujimoto H, Nonomura N, Hongo F, Sugiyama T, Takahashi M, Kanayama HO, Fukumori T, Eto M:, Perinephric invasion as a prognostic factor in non-metastatic renal cell carcinoma: analysis of a nation-wide registry program., Jpn J Clin Oncol, 49 (8): 772-779, 2019.08. |
| 153. |
Shiota M, Ushijima M, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Kajioka S, Eto M:, Cigarette smoking augments androgen receptor activity and promotes resistance to antiandrogen therapy., Prostate, 79 (10): 1147-1155, 2019.07. |
| 154. |
Hiraki Y, Okamoto D, Nishie A, Asayama Y, Ishigami K, Ushijima Y, Takayama Y, Fujita N, Eto M, Kinoshita F, Honda H:, Papillary renal cell carcinoma with massive hematoma mimicking hemangioma., Radiol Case Rep, 14 (8): 1003-1006, 2019.06. |
| 155. |
Kobayashi T, Namitome R, Hirata YU, Shiota M, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Eto M:, Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With De Novo Metastatic Prostate Cancer., Anticancer Res, 39 (6): 3191-3195, 2019.06. |
| 156. |
Kurahashi R, Kadomatsu T, Baba M, Hara C, Itoh H, Miyata K, Endo M, Morinaga J, Terada K, Araki K, Eto M, Schmidt LS, Kamba T, Linehan WM, Oike Y:, MicroRNA‐204‐5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma., Cancer Sci, 110 (6): 1897-1908, 2019.06. |
| 157. |
Shiota M, Fujimoto N, Tsukahara S, Ushijima M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Uchiumi T, Eto M:, Genetic Polymorphism in Sex Hormone-binding Globulin With a Prognosis of Androgen Deprivation Therapy in Metastatic Prostate Cancer Among Japanese Men., Clin Genitourin Cancer, 17 (3): e387-e393, 2019.06. |
| 158. |
Mikami S, Mizuno R, Kondo T, Shinohara N, Nonomura N, Ozono S, Eto M, Tatsugami K, Takayama T, Matsuyama H, Kishida T, Oya M; Japanese Society of Renal Cancer:, Clinical significance of programmed death‐1 and programmed death‐ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma., Cancer Sci, 110 (6): 1820-1828, 2019.06. |
| 159. |
Tomita Y, Fukasawa S, Shinohara N, Kitamura H, Oya M, Eto M, Tanabe K, Saito M, Kimura G, Yonese J, Yao M, Uemura H:, Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study., Jpn J Clin Oncol, 49 (6): 506-514, 2019.06. |
| 160. |
Shiota M, Fujimoto N, Tsukahara S, Ushijima M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Uchiumi T, Eto M:, The impact of genetic polymorphism on CYP19A1 in androgen-deprivation therapy among Japanese men., Cancer Chemother Pharmacol, 83 (5): 933-938, 2019.05. |
| 161. |
Osawa T, Takeuchi A, Kojima T, Shinohara N, Eto M, Nishiyama H:, Overview of current and future systemic therapy for metastatic renal cell carcinoma., Jpn J Clin Oncol, 49 (5): 395-403, 2019.05. |
| 162. |
Maki T, Kajioka S, Itsumi M, Kareman E, Lee K, Shiota M, Eto M:, Mirabegron induces relaxant effects via cAMP signaling-dependent and -independent pathways in detrusor smooth muscle., Low Urin Tract Symptoms, 11 (2): O209-O217, 2019.04. |
| 163. |
Grünwald V, Powles T, Choueiri TK, Hutson TE, Porta C, Eto M, Sternberg CN, Rha SY, He CS, Dutcus CE, Smith A, Dutta L, Mody K, Motzer RJ:, Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale., Future Oncol, 15 (9): 929-941, 2019.03. |
| 164. |
Shiota M, Namitome R, Kobayashi T, Inokuchi J, Tatsugami K, Eto M:, Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer., Int J Urol, 26 (3): 426-428, 2019.03. |
| 165. |
Shiota M, Kashiwagi E, Murakami T, Takeuchi A, Imada K, Inokuchi J, Tatsugami K, Eto M:, Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer., Urol Oncol, 37 (3): 180.e19-180.e24, 2019.03. |
| 166. |
Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M:, Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study., Med Oncol, 36 (4): 32, 2019.02. |
| 167. |
Shiota M, Narita S, Akamatsu S, Fujimoto N, Sumiyoshi T, Fujiwara M, Uchiumi T, Habuchi T, Ogawa O, Eto M:, Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone., JAMA Netw Open, 2 (2): e190115, 2019.02. |
| 168. |
Murakami Y, Naganuma H, Tanigawa S, Fujimori T, Eto M, Nishinakamura R:, Reconstitution of the embryonic kidney identifies a donor cell contribution to the renal vasculature upon transplantation., Sci Rep, 9 (1): 1172, 2019.02. |
| 169. |
Umezu D, Okada N, Sakoda Y, Adachi K, Ojima T, Yamaue H, Eto M, Tamada K:, Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment., Cancer Immunol Immunother, 68 (2): 201-211, 2019.02. |
| 170. |
Harada K, Nozawa M, Uemura M, Tatsugami K, Osawa T, Yamana K, Kimura G, Fujisawa M, Nonomura N, Eto M, Shinohara N, Tomita Y, Kondo Y, Ochi K, Anazawa Y, Uemura H:, Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan., Int J Urol, 26 (2): 202-210, 2019.02. |
| 171. |
Shiota M, Fujimoto N, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Eto M:, Prognostic Impact of Genetic Polymorphism in Mineralocorticoid Receptor and Comorbidity With Hypertension in Androgen-Deprivation Therapy., Front Oncol, 8: 635, 2018, 2018.12. |
| 172. |
Gross-Goupil M, Kwon TG, Eto M, Ye D, Miyake H, Seo SI, Byun SS, Lee JL, Master V, Jin J, DeBenedetto R, Linke R, Casey M, Rosbrook B, Lechuga M, Valota O, Grande E, Quinn DI:, Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial., Ann Oncol 29, 29 (12): 2371-2378, 2018, 2018.12. |
| 173. |
Ito K, Mikami S, Tatsugami K, Masumori N, Shinohara N, Kondo T, Nakanishi S, Nagashima Y, Eto M, Kamba T, Kuroda N, Tomita Y, Matsuyama H, Onishi T, Tsushima T, Nakazawa H, Oya M, Ozono S, Naito S, Asano T:, Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan., Clin Genitourin Cancer, 16 (6): e1201-e1214, 2018, 2018.12. |
| 174. |
Shiota M, Kashiwagi E, Murakami T, Takeuchi A, Imada K, Inokuchi J, Tatsugami K, Eto M:, Serum testosterone before and during androgen-deprivation therapy, and prognosis between cigarette smokers and nonsmokers with metastatic prostate cancer., Andrologia, 50 (10): e13119, 2018, 2018.12. |
| 175. |
Murakami T, Otsubo S, Namitome R, Shiota M, Inokuchi J, Takeuchi A, Kashiwagi E, Tatsugami K, Eto M:, Clinical factors affecting perioperative outcomes in robot-assisted radical prostatectomy., Mol Clin Oncol 9 (5): 575-581, 2018, 9 (5): 575-581, 2018, 2018.11. |
| 176. |
Takahashi R, Kimoto Y, Eto M:, Long-term urodynamic follow-up after external sphincterotomy in patients with spinal cord injury., Neurourol Urodyn, 37 (8): 2625-263, 2018, 2018.11. |
| 177. |
Abe T, Kohashi K, Takemoto J, Kinoshita F, Eto M, Oda Y:, Clinicopathological Significance and Antitumor Effect of MPHOSPH1 in Testicular Germ Cell Tumor., J Cancer, 9 (23): 4440-4448, 2018, 2018.10. |
| 178. |
Shiota M, Dejima T, Yamamoto Y, Takeuchi A, Imada K, Kashiwagi E, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Eto M:, Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants., Cancer Sci, 109 (10): 3224-3234, 2018, 2018.10. |
| 179. |
Akitake N, Shiota M, Obata H, Takeuchi A, Kashiwagi E, Imada K, Kiyoshima K, Inokuchi J, Tatsugami K, Eto M:, Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone., Prostate Int, 6 (3): 104-109,2018, 2018.09. |
| 180. |
Inoue M, Okamura K, Kitaoka C, Kinoshita F, Namitome R, Nakamura U, Shiota M, Goto K, Ohtsubo T, Matsumura K, Oda Y, Eto M, Kitazono T:, Metyrapone-responsive ectopic ACTH-secreting pheochromocytoma with a vicious cycle via a glucocorticoid-driven positive-feedback mechanism., Endocr J, 65 (7): 755-767, 2018, 2018.07. |
| 181. |
Tanaka K, Yanagihara T, Ikematsu Y, Inoue H, Ota K, Kashiwagi E, Suzuki K, Hamada N, Takeuchi A, Tatsugami K, Eto M, Ijichi K, Oda Y, Otsubo K, Yoneshima Y, Iwama E, Nakanishi Y, Okamoto I:, Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade., Oncotarget, 9 (55): 30587-30593, 2018, 2018.07. |
| 182. |
Murakami T, Obata H, Akitake N, Shiota M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Eto M:, Prognostic and Predictive Factors for Anti-androgen Withdrawal in Castration-resistant Prostate Cancer., Anticancer Res, 38 (7): 4115-4121, 2018, 2018.07. |
| 183. |
Akitake M, Kiyoshima K, Yokomizo A, Shiga K, Koga H, Takeuchi A, Shiota M, Inokuchi J, Tatsugami K, Yamaguchi A, Eto M:, A rational risk assessment for intravesical recurrence in primary low-grade Ta bladder cancer: A retrospective analysis of 245 cases., Mol Clin Oncol, 8 (6): 785-790, 2018, 2018.06. |
| 184. |
Morizane S, Honda M, Fukasawa S, Komaru A, Inokuchi J, Eto M, Shimbo M, Hattori K, Kawano Y, Takenaka A:, Comparison of the diagnostic efficacy and perioperative outcomes of limited versus extended pelvic lymphadenectomy during robot-assisted radical prostatectomy: a multi-institutional retrospective study in Japan., Int J Clin Oncol, 23 (3): 568-575, 2018, 2018.06. |
| 185. |
藤本直浩、守屋良介、岩隈景子、久保達彦、久岡正典、野口 満、有働和馬、内藤誠二、江藤正俊、横溝 晃、三股浩光、澁谷忠正、賀本敏行、分田裕順、井川 掌、西原聖顕、酒井英樹、竹原浩介、計屋知彰、中川昌之、山根隆史、神波大己、河野吉昭、斎藤誠一、安次嶺 聡、大城吉則、田中正利、古屋隆三郎、石井 龍：, 実臨床に有用な後腹膜腫瘍の特徴
－第19回九州泌尿器科共同研究 九州沖縄地区における後腹膜腫瘍の実態調査サブ解析－．, 西日泌尿, 80 (3): 91-96, 2018, 2018.03. |
| 186. |
Reix B, Bernhard JC, Patard JJ, Bigot P, Villers A, Suer E, Vuong NS, Verhoest G, Alimi Q, Beauval JB, Benoit T, Nouhaud FX, Lenormand C, Hamidi N, Cai J, Eto M, Larre S, El Bakhri A, Ploussard G, Hung A, Koutlidis N, Schneider A, Carrouget J, Droupy S, Marchal S, Doerfler A, Seddik S, Matsugasumi T, Orsoni X, Descazeaud A, Pfister C, Bensalah K, Soulie M, Gill I, Flamand V; Kidney Cancer group of the CCAFU:, Overall survival and oncological outcomes after partial nephrectomy and radical nephrectomy for cT2a renal tumors: A collaborative international study from the French kidney cancer research network UroCCR., Prog Urol, 28 (3): 146-155, 2018, 2018.03. |
| 187. |
Shiota M, Fujimoto N, Takeuchi A, Kashiwagi E, Dejima T, Inokuchi J, Tatsugami K, Yokomizo A, Kajioka S, Uchiumi T, Eto M:, The Association of Polymorphisms in the Gene Encoding Gonadotropin-Releasing Hormone with Serum Testosterone Level during Androgen Deprivation Therapy and Prognosis of Metastatic Prostate Cancer., J Urol, 199 (3): 734-740, 2018, 2018.03. |
| 188. |
Takeuchi A, Kato K, Akashi K, Eto M:, Cyclophosphamide-induced tolerance in kidney transplantation avoids long-term immunosuppressive therapy., Int J Urol, 25 (2): 112-120, 2018, 2018.02. |
| 189. |
Tsuruta M, Ueda S, Yew PY, Fukuda I, Yoshimura S, Kishi H, Hamana H, Hirayama M, Yatsuda J, Irie A, Senju S, Yuba E, Kamba T, Eto M, Nakayama H, Nishimura Y:, Bladder cancer-associated cancer-testis antigen-derived long peptides encompassing both CTL and promiscuous HLA class II-restricted Th cell epitopes induced CD4+ T cells expressing converged T-cell receptor genes in vitro., Oncoimmunology, 7 (4): e1415687, 2018, 2018.01. |
| 190. |
Takahashi R, Miyazato M, Nishii H, Sumino Y, Takayama K, Onzuka M, Oshiro T, Saito S, Fujimoto N, Mimata H, Eto M:, Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study)., Low Urin Tract Symptoms, 10 (1): 76-83, 2018, 2018.01. |
| 191. |
Lee K, Isogai A, Antoh M, Kajioka S, Eto M, Hashitani H:, Role of K+ channels in regulating spontaneous activity in the muscularis mucosae of guinea pig bladder., Eur J Pharmacol, 818: 30-37, 2018, 2018.01. |
| 192. |
Fujimoto N, Kubo T, Hisaoka M, Udo K, Yokomizo A, Shibuya T, Wakeda H, Nishihara K, Moriya R, Iwakuma K; Kyushu Cooperative Urological Research Group:, Demographics, management and treatment outcomes of benign and malignant retroperitoneal tumors in Japan., Int J Urol, 25 (1): 61-67, 2018, 2018.01. |
| 193. |
Hara T, Fujimoto H, Kondo T, Shinohara N, Obara W, Kimura G, Kume H, Nonomura N, Hongo F, Sugiyama T, Kanayama HO, Takahashi M, Fukumori T, Eto M; Cancer Registration Committee of the Japanese Urological Association., Active heavy cigarette smoking is associated with poor survival in Japanese patients with advanced renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological Association., Jpn J Clin Oncol, 47 (12): 1162-1169, 2017, 2017.12. |
| 194. |
Masaoka H, Matsuo K, Sawada N, Yamaji T, Goto A, Shimazu T, Iwasaki M, Inoue M, Eto M, Tsugane S; Japan Public Health Center-based Prospective Study Group:, Alcohol consumption and bladder cancer risk with or without the flushing response: The Japan Public Health Center-based Prospective Study., Int J Cancer, 141 (12): 2480-2488, 2017, 2017.12. |
| 195. |
Matsumoto T, Uchiumi T, Monji K, Yagi M, Setoyama D, Amamoto R, Matsushima Y, Shiota M, Eto M, Kang D:, Doxycycline induces apoptosis via ER stress selectively to cells with a cancer stem cell-like properties: importance of stem cell plasticity., Oncogenesis, 6 (11): 397, 2017, 2017.11. |
| 196. |
Inokuchi J, Kuroiwa K, Kakehi Y, Sugimoto M, Tanigawa T, Fujimoto H, Gotoh M, Masumori N, Ogawa O, Eto M, Ohyama C, Yamaguchi A, Matsuyama H, Ichikawa T, Asano T, Mizusawa J, Eba J, Naito S:, Role of lymph node dissection during radical nephroureterectomy for upper urinary tract urothelial cancer: multi-institutional large retrospective study JCOG1110A., World J Urol, 35 (11): 1737-1744, 2017, 2017.11. |
| 197. |
Obata H, Shiota M, Akitake N, Takeuchi A, Kashiwagi E, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K, Eto M:, Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer., Anticancer Res, 37 (10): 5631-5637, 2017, 2017.10. |
| 198. |
Iida Y, Harashima N, Motoshima T, Komohara Y, Eto M, Harada M:, Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models., Cancer Sci, 108 (10): 1974-1984, 2017, 2017.10. |
| 199. |
Yamaguchi K, Inoue T, Habuchi T, Inokuchi J, Yokomizo A, Eto M, Kanayama HO:, An In Vitro Study of a New Device: Evaluation of Novel Wide-Angle Lens Flexible Cystoscope Using Phantom Bladder Model., J Endourol, 31 (10): 1073-1078, 2017, 2017.10. |
| 200. |
Masaoka H, Gallus S, Ito H, Watanabe M, Yokomizo A, Eto M, Matsuo K:, Aldehyde Dehydrogenase 2 Polymorphism Is a Predictor of Smoking Cessation., Nicotine Tob Res, 19 (9): 1087-1094, 2017, 2017.09. |
| 201. |
Masaoka H, Ito H, Yokomizo A, Eto M, Matsuo K:, Potential overtreatment among men aged 80 years and older with localized prostate cancer in Japan., Cancer Sci
, 108 (8): 1673-1680, 2017, 2017.08. |
| 202. |
Yanagihara T, Tanaka K, Ota K, Kashiwagi E, Takeuchi A, Tatsugami K, Eto M, Nakanishi Y, Okamoto I:, Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment., Ann Oncol, 28 (8): 2038-2039, 2017, 2017.08. |
| 203. |
Inokuchi J, Eto M, Hara T, Fujimoto H, Nishiyama H, Miyazaki J, Kikuchi E, Hinotsu S, Koie T, Ohyama C; Cancer Registration Committee of the Japanese Urological Association:, Impact of lymph node dissection on clinical outcomes during nephroureterectomy in patients with clinically node-negative upper urinary tract urothelial cancer: subanalysis of a multi-institutional nationwide case series of the Japanese Urological Association., Jpn J Clin Oncol, 47 (7): 652-659, 2017, 2017.07. |
| 204. |
Tomita Y, Fukasawa S, Shinohara N, Kitamura H, Oya M, Eto M, Tanabe K, Kimura G, Yonese J, Yao M, Motzer RJ, Uemura H, McHenry MB, Berghorn E, Ozono S:, Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study., Jpn J Clin Oncol, 47 (7): 639-646, 2017, 2017.07. |
| 205. |
Sato N, Shiota M, Shiga KI, Takeuchi A, Inokuchi J, Tatsugami K, Yokomizo A, Koga H, Yamaguchi A, Naito S, Eto M:, Smoking effect on oncological outcome among men with prostate cancer after radical prostatectomy., Jpn J Clin Oncol, 47 (5): 453-457, 2017, 2017.05. |
| 206. |
Shiota M, Takeuchi A, Sugimoto M, Kashiwagi E, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K, Yokomizo A, Eto M:, The Differential Impact of Body Mass Index and the Feature of Metabolic Syndrome on Oncological Outcomes Following Different Surgical Procedures in Japanese Men with Prostate Cancer., Ann Surg Oncol, 24 (5): 1443-1450, 2017, 2017.05. |
| 207. |
Shiota M, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Inokuchi J, Tatsugami K, Uchiumi T, Eto M:, Protein kinase C regulates Twist1 expression via NF-κB in prostate cancer., Endocr Relat Cancer, 24 (4): 171-180, 2017, 2017.04. |
| 208. |
Obara W, Eto M, Mimata H, Kohri K, Mitsuhata N, Miura I, Shuin T, Miki T, Koie T, Fujimoto H, Minami K, Enomoto Y, Nasu T, Yoshida T, Fuse H, Hara I, Kawaguchi K, Arimura A, Fujioka T:, A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder., Ann Oncol, 28 (4): 798-803, 2017, 2017.04. |
| 209. |
Masaoka H, Ito H, Gallus S, Watanabe M, Yokomizo A, Eto M, Matsuo K:, Combination of ALDH2 and ADH1B polymorphisms is associated with smoking initiation: A large-scale cross-sectional study in a Japanese population., Drug Alcohol Depend, 173: 85-91, 2017, 2017.04. |
| 210. |
Shiota M, Fujimoto N, Itsumi M, Takeuchi A, Inokuchi J, Tatsugami K, Yokomizo A, Kajioka S, Uchiumi T, Eto M:, Gene polymorphisms in antioxidant enzymes correlate with the efficacy of androgen-deprivation therapy for prostate cancer with implications of oxidative stress., Ann Oncol, 28 (3): 569-575, 2017, 2017.03. |
| 211. |
Tatsugami K, Yoshioka K, Shiroki R, Eto M, Yoshino Y, Tozawa K, Fukasawa S, Fujisawa M, Takenaka A, Nasu Y, Kashiwagi A, Gotoh M, Terachi T; Japanese Society of Endourology:, Reality of nerve sparing and surgical margins in surgeons' early experience with robot-assisted radical prostatectomy in Japan., Int J Urol, 24 (3): 191-196, 2017, 2017.03. |
| 212. |
Imada K, Shiota M, Kuroiwa K, Sugimoto M, Abe T, Kohashi K, Yokomizo A, Eto M, Naito S, Oda Y:, FOXO3a Expression Regulated by ERK Signaling is Inversely Correlated With Y-Box Binding Protein-1 Expression in Prostate Cancer., Prostate, 77 (2): 145-153, 2017, 2017.02. |
| 213. |
Shiota M, Kiyoshima K, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Takahashi R, Inokuchi J, Tatsugami K, Eto M:, Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5α-Reductase Inhibitor., J Urol, 197 (2): 308-313, 2017, 2017.02. |
| 214. |
Bigot P, Bernhard JC, Flamand V, Gill I, Verhoest G, Beauval JB, Nouhaud FX, Suer E, Ploussard G, Hetet JF, Rigaud J, Baco E, Larré S, Sebe P, Koutlidis N, Descazeaud A, Eto M, Doerfler A, Roupret M, Vuong NS, Reix B, Matsugasumi T, Bakri AE, Albiges L, Soulié M, Patard JJ, Méjean A, Bensalah K; members of the Kidney Cancer group of the CCAFU:, Localized chromophobe carcinomas treated by nephron-sparing surgery have excellent oncologic outcomes., Urol Oncol, 35 (1): 35.e15-35.e19, 2017, 2017.01. |
| 215. |
Motoshima T, Komohara Y, Ma C, Dewi AK, Noguchi H, Yamada S, Nakayama T, Kitada S, Kawano Y, Takahashi W, Sugimoto M, Takeya M, Fujimoto N, Oda Y, Eto M:, PD-L1 expression in papillary renal cell carcinoma., BMC Urol, 17 (1): 8, 2017, 2017.01. |
| 216. |
猪口 淳一, 波止 亮, 清島 圭二郎, 武内 在雄, 塩田 真己, 高橋 良輔, 立神 勝則, 横溝 晃, 江藤 正俊, ロボット手術時代における前立腺癌リンパ節転移予測ノモグラムの妥当性．, 西日泌尿, 78 (9): 451-456, 2016, 2016.09. |
| 217. |
Shiota M, Yokomizo A, Takeuchi A, Kiyoshima K, Inokuchi J, Tatsugami K, Shiga KI, Koga H, Yamaguchi A, Naito S, Eto M, Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare., BJU Int, 118 (6): 880-884, 2016, 2016.12. |
| 218. |
Wada Y, Maeda Y, Kubo T, Kikuchi K, Eto M, Imamura T, C5a receptor expression is associated with poor prognosis in urothelial cell carcinoma patients treated with radical cystectomy or nephroureterectomy., Oncol Lett, 12 (5): 3995-4000, 2016, 2016.11. |
| 219. |
Shiota M, Yokomizo A, Takeuchi A, Inokuchi J, Tatsugami K, Ohga S, Sasaki T, Nakamura K, Honda H, Eto M, Smoking effect on secondary bladder cancer after external beam radiotherapy for prostate cancer., Jpn J Clin Oncol, 46 (10): 952-957, 2016, 2016.10. |
| 220. |
Takahashi S, Hamasuna R, Yasuda M, Ishikawa K, Hayami H, Uehara S, Yamamoto S, Minamitani S, Kadota J, Iwata S, Eto M, et al., Nationwide surveillance of the antimicrobial susceptibility of Chlamydia trachomatis from male urethritis in Japan., J Infect Chemother, 22 (9): 581-586, 2016, 2016.09. |
| 221. |
Miyazato M, Oshiro T, Saito S, Takahashi R, Eto M, Nishi H, Fujimoto N, Sumino Y, Miyata H, Arai K, Kinjo T, Effects of switching from alpha-blocker to tadalafil in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (KYU-PRO STUDY)., Nishinihon J Urol, 78: 398-405, 2016, 2016.08. |
| 222. |
Itsumi M, Shiota M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Naito S, Eto M, Yokomizo A, Equol inhibits prostate cancer growth through degradation of androgen receptor by S-phase kinase-associated protein 2., Cancer Sci, 107 (7): 1022-1028, 2016, 2016.07. |
| 223. |
Kawano Y, Takahashi W, Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K,, Nakamura T, Ogawa O, Naito S, Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy., Cancer Sci, 107 (7): 1013-1017, 2016, 2016.07. |
| 224. |
Shiota M, Fujimoto N, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K, Eto M, The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism., Prostate Cancer Prostatic Dis, 19 (2): 191-196, 2016, 2016.06. |
| 225. |
Masaoka H, Ito H, Soga N, Hosono S, Oze I, Watanabe M, Tanaka H, Yokomizo A, Hayashi N, Eto M, Matsuo K, Aldehyde dehydrogenase 2 (ALDH2) and alcohol dehydrogenase 1B (ADH1B) polymorphisms exacerbate bladder cancer risk associated with alcohol drinking: gene-environment interaction., Carcinogenesis, 37 (6): 583-588, 2016, 2016.06. |
| 226. |
Takeuchi A, Eto M, Tatsugami K, Shiota M, Yamada H, Kamiryo Y, Dejima T, Kashiwagi E, Kiyoshima K, Inokuchi J, Takahashi R, Yokomizo A, Ohara N, Yoshikai Y, Antitumor activity of recombinant Bacille Calmette-Guérin secreting interleukin-15-Ag85B fusion protein against bladder cancer., Int Immunopharmacol, 35: 327-331, 2016, 2016.06. |
| 227. |
Koie T, Ohyama C, Fujimoto H, Nishiyama H, Miyazaki J, Hinotsu S, Kikuchi E, Sakura M, Inokuchi J, Hara T, Cancer Registration Committee of the Japanese Urological Association, Ohyama C, Nishiyama H, Fujisawa M, Uemura H, Fujimoto H, Suzuki K, Eto M, et al., Diversity in treatment modalities of Stage II/III urothelial cancer in Japan: sub-analysis of the multi-institutional national database of the Japanese Urological Association., Jpn J Clin Oncol, 46 (5): 468-474, 2016, 2016.05. |
| 228. |
Ma C, Komohara Y, Ohnishi K, Shimoji T, Kuwahara N, Sakumura Y, Matsuishi K, Fujiwara Y, Motoshima T, Takahashi W, Yamada S, Kitada S, Fujimoto N, Nakayama T, Eto M, Takeya M, Infiltration of tumor-associated macrophages is involved in CD44 expression in clear cell renal cell carcinoma., Cancer Sci, 107 (5): 700-707, 2016, 2016.05. |
| 229. |
Inokuchi J, Seiji Naito, Fujimoto H, Hara T, Sakura M, Nishiyama H, Miyazaki J, Kikuchi E, Hinotsu S, Koie T, Ohyama C, Cancer Registration Committee of the Japanese Urological Association, Impact of multimodal treatment on prognosis for patients with metastatic upper urinary tract urothelial cancer: Subanalysis of the multi-institutional nationwide case series study of the Japanese Urological Association., Int J Urol, 23 (3): 224-230, 2016, 2016.03. |
| 230. |
Bigot P, Bernhard JC, Gill IS, Vuong NS, Verhoest G, Flamand V, Reix B, Suer E, Gökce I, Beauval JB, Nouhaud FX, Eto M, et al., The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery., World J Urol, 34 (3): 347-352, 2016, 2016.03. |
| 231. |
Motoshima T, Komohara Y, Horlad H, Tsukamoto H, Fujita M, Saito Y, Tanoue K, Kasejima Y, Sugiyama Y, Kawano Y, Nishimura Y, Takeya M, Eto M, CXCL10 and CCL2 mRNA expression in monocytes is inversely correlated with the HLA-DR lower fraction of monocytes in patients with renal cell carcinoma., Oncol Lett, 11 (3): 1911-1916, 2016, 2016.03. |
| 232. |
Shiota M, Eto M, Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer., Int J Urol, 23 (5): 360-369, 2016, 2016.03. |
| 233. |
Kiyoshima K, Akitake M, Shiota M, Takeuchi A, Takahashi R, Inokuchi J, Tatsugami K, Yokomizo A, Eto M, Prognostic Significance of Preoperative Urine Cytology in Low-grade Non-muscle-invasive Bladder Cancer., Anticancer Res, 36 (2): 799-802, 2016, 2016.02. |
| 234. |
Shiota M, Yokomizo A, Eto M, Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy., Front Oncol, 5 :304, 2016, 2016.01. |
| 235. |
Noguchi M, Matsumoto K, Uemura H, Arai G, Eto M, Naito S, Ohyama C, Nasu Y, Tanaka M, Moriya F, Suekane S, Matsueda S, Komatsu N, Sasada T, Yamada A, Kakuma T, Itoh K, An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy., Clin Cancer Res, 22 (1): 54-60, 2016, 2016.01. |
| 236. |
Hara T, Fujimoto H, Sakura M, Inokuchi J, Nishiyama H, Miyazaki J, Ohyama C, Koie T, Kikuchi E, Hinotsu S, Cancer Registration Committee of the Japanese Urological Association, Prognostic factors of recurrent disease in upper urinary tract urothelial cancer after radical nephroureterectomy: Subanalysis of the multi-institutional national database of the Japanese Urological Association., Int J Urol, 22 (11): 1013-1020, 2015, 2015.11. |
| 237. |
Miyazaki J, Nishiyama H, Fujimoto H, Ohyama C, Koie T, Hinotsu S, Kikuchi E, Sakura M, Inokuchi J, Hara T, Cancer Registration Committee of the Japanese Urological Association, Impact of smoking on the age at diagnosis of upper tract urothelial carcinoma: Subanalysis of the Japanese Urological Association multi-institutional national database., Int J Urol, 22 (11): 1023-1027, 2015, 2015.11. |
| 238. |
Eto M, Kawano Y, Hirao Y, Mita K, Arai Y, Tsukamoto T, Hashine K, Matsubara A, Fujioka T, Kimura G, Shinohara N, Tatsugami K, Hinotsu S, Naito S, Japan RCC Trialist Collaborative Group (JRTCG) investigators, Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan., BMC Cancer, 15: 667, 2015, 2015.10. |
| 239. |
Kanayama HO, Fukumori T, Fujimoto H, Nakanishi H, Ohyama C, Suzuki K, Nishiyama H, Eto M, Miki T, Kamoi K, Kubota Y, Takahashi S, Homma Y, Naito S, Clinicopathological characteristics and oncological outcomes in patients with renal cell carcinoma registered in 2007: The first large-scale multicenter study from the Cancer Registration Committee of the Japanese Urological Association., Int J Urol, 22 (9): S1-S7, 2015, 2015.09. |
| 240. |
Naito S, Sakai H, Hashine K, Tomita Y, Shinohara N, Fujisawa M, Eto M, Ozono S, Akaza H, Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma., Ann Oncol, 26 (9): 1871-1876, 2015, 2015.09. |
| 241. |
Tatsugami K, Shinohara N, Kondo T, Yamasaki T, Eto M, Tsushima T, Terachi T, Naito S, Japanese Society of Renal Cancer, Role of cytoreductive nephrectomy for Japanese patients with primary renal cell carcinoma in the cytokine and targeted therapy era., Int J Urol, 22 (8): 736-740, 2015 , 2015.08. |
| 242. |
Motoshima T, Komohara Y, Horlad H, Takeuchi A, Maeda Y, Tanoue K, Kawano Y, Harada M, Takeya M, Eto M, Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells., Oncol Rep, 33 (6): 2947-2953, 2015, 2015.06. |
| 243. |
Maeda Y, Kawano Y, Wada Y, Yatsuda J, Motoshima T, Murakami Y, Kikuchi K, Imamura T, Eto M, C5aR is frequently expressed in metastatic renal cell carcinoma and plays a crucial role in cell invasion via the ERK and PI3 kinase pathways., Oncol Rep, 33 (4): 1844-1850, 2015, 2015.04. |
| 244. |
Eto M, IJU this issue., Int J Urol, 22 (3): 241, 2015, 2015.03. |
| 245. |
Takeuchi A, Eto M, Tatsugami K, Yamada H, Yokomizo A, Shiota M, Itsumi M, Inokuchi J, Kiyoshima K, Dejima T, Imada K, Naito S, Yoshikai S, Renal cancer treatment with recipient lymphocyte infusion enhanced the antitumor effect of nonmyeloablative allogeneic stem cell transplantation., Transpl Immunol, 32 (2): 131-139, 2015, 2015.03. |
| 246. |
Hamaguchi M, Eto M, Kamiryo Y, Takeuchi A, Harano M, Tatsugami K, Teshima T, Harada M, Yoshikai Y, Naito S:, Allogeneic cell therapy from immunized donors with tumor antigen peptide enhances the antitumor effect after cyclophosphamide-using non-myeloablative allogeneic hematopoietic cell transplantation., Cancer Sci , 100 (1): 138-143, 2009, 2009.01. |
| 247. |
Tatsugami K, Eto M, Hamaguchi M, Yokomizo Y, Harano M, Naito S:, What affects the results of a laparoscopic adrenalectomy for pheochromocytoma? Evaluation with respect to intraoperative blood pressure and state of tumor., J Endourol , 23 (1): 101-195, 2009, 2009.01. |
| 248. |
原野正彦、江藤正俊、濱口益光、立神勝則、上領頼之、内藤誠二：, 小径腎癌に対する腎部分切除術の有用性・安全性の検討－根治的腎摘除術との比較－., 西日泌尿 , 70 (11): 587-591, 2008, 2008.11. |
| 249. |
Tatsugami K, Eto M, Harano M, Hamaguchi M, Miyamoto T, Morisaki T, Furue M, Akashi K, Naito S:, Dendritic cell therapy in combination with interferon-α for the treatment of metastatic renal cell carcinoma., Int J Urol , 15 (8): 694-698, 2008, 2008.08. |
| 250. |
Harano M, Eto M, Yokomizo A, Tatsugami K, Hamaguchi M, Naito S:, The efficacy of laparoscopic radical nephrectomy for renal cell cancer in the elderly: an oncological outcome analysis., Int J Urol , 15 (7): 577-581, 2008, 2008.07. |
| 251. |
Eto M, Kamiryo Y, Takeuchi A, Harano M, Tatsugami K, Harada M, Kiyoshima K, Hamaguchi M, Teshima T, Tsuneyoshi M, Yoshikai Y, Naito S:, Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor., Clin Cancer Res , 14 (9):2833-2840, 2008, 2008.05. |
| 252. |
Eto M, Hamaguchi M, Harano M, Yokomizo A, Tatsugami K, Naito S:, Laparoscopic adrenalectomy for malignant tumors., Int J Urol , 15 (4): 295-298, 2008, 2008.04. |
| 253. |
Eto M, Lee TY, Gill IS, Koga H, Tatsugami K, Shimizu S, Ukimura O, Naito S:, Broadcast of live endoscopic surgery from Korea to Japan using the digital video transport system., J Endourol , 21 (12): 1517-1520, 2007, 2007.12. |
| 254. |
Harano M, Eto M, Yokomizo A, Tatsugami K, Hamaguchi M, Naito S:, Comparison of standard and hand-assised laparoscopic radical nephrectomy for renal cell carcinoma., Fukuoka Acta Med , 98 (11): 389-396, 2007, 2007.11. |
| 255. |
Ito N, Eto M, Nakamura E, TakahashiA, Tsukamoto T, Toma H, Nakazawa H, Hirao Y, Uemura H, Kagawa S, Kanayama H, Nose Y, Kinukawa N, Nakamura T, Jinnai N, Seki T, Takamatsu M, Masui Y, Naito S, Ogawa O:, STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma., J Clin Oncol , 25 (19): 2785-2791, 2007, 2007.07. |
| 256. |
Eto M, Ieiri S, Tanoue K, Hashizume M, Naito S:, Training of robotic surgery in Kyushu University Hospital., Recent Advances in Endourology Proceedings of the 3rd Annual Meeting of EASE 10:, 6-14, 2007, 2007.04. |
| 257. |
Harano M, Eto M, Nakamura M, Hasegawa Y, Kano M, Yamaguchi A, Naito S:, A pilot study of the assessment of the quality of life, functional results, and complications in patients with an ileal neobladder for invasive bladder cancer., Int J Urol , 14 (2): 112-117, 2007, 2007.02. |
| 258. |
Eto M, Harano M, Tatsugami K, Harada M, Kamiryo Y, Kiyoshima K, Hamaguchi M, Tsuneyoshi M, Yoshikai Y, Naito S:, Cyclophosphamide-using nonmyeloablative allogeneic cell therapy against renal cancer with a reduced risk of graft-versus-host disease., Clin Cancer Res , 13 (3): 1029-1035, 2007, 2007.02. |
| 259. |
原野正彦、江藤正俊、甲斐信幸、内藤誠二、中村元信、長谷川淑博、山口秋人、加野資典：, 回腸利用代用膀胱造設術の日常生活QOL・術後合併症・oncological outcome・腎機能推移について－cutaneous diversion症例との比較検討－., 西日泌尿, 68 (10): 459-465, 2006, 2006.10. |
| 260. |
Eto M, Harano M, Koga H, Tanaka M, Naito S:, Clinical outcomesand learning curve of a laparoscopic adrenalectomy in 103 consecutive cases at a single institute., Int J Urol , 13 (6): 671-676, 2006 , 2006.06. |
| 261. |
Ichikura H, Eto M, Ueno H,Harada M, Takayama K, Tokuda N, Tatsugami K, Naito S:, In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor., Oncol Rep, 15 (5): 1333-1337, 2006, 2006.05. |
| 262. |
Eto M, J Bennouna, OC Hunter,MT Lotze, AA Amoscato:, Importance of C16 ceramide accumulation during apoptosis in prostate cancer cells., Int J Urol , 13 (2): 148-156, 2006, 2006.02. |
| 263. |
Harano M, Tokuda N, Ichikura H, Nakamura M,Eto M, Tatsugami K, Naito S:, The change of the split renal function before and after a nephrectomy using Tc-mercaptoacetyltriglycine (MAG3)., Fukuoka Acta Med, 96 (12): 391-398, 2005, 2005.12. |
| 264. |
Harano M, Eto M, Iwai T, Tatsugami K, Kiyoshima K, Kamiryo Y, Tsuneyoshi M, Yoshikai Y, Naito S:, Renal cancer treatment with low levels of mixed chimerism induced by nonmyeloablative regimen using cyclophosphamide in mice., Cancer Res, 65 (21): 10032-10040, 2005, 2005.11. |
| 265. |
Eto M, Koga H, Noma H, Yamaguchi A, Yoshikai Y, Naito S:, Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guerin for superficial bladder tumors., Urol Int, 75 (2): 114-118, 2005, 2005.09. |
| 266. |
Harano M, Eto M, Omoto K, Tatsugami K, Nomura H, Koga H, Hojyo M,Yamaguchi A, Naito S:, Long-term outcome of hand-assisted laparoscopic radical nephrectomy for localized stage T1/T2 renal-cell carcinoma., J Endourol , 19 (7): 803-807, 2005, 2005.09. |
| 267. |
Eto M, Harada M,Tatsugami K, Harano M, Koga H, Matsuzaki G,Naito S:, Anti-tumour activity of heat-shock protein 60-recognizing CD4+ T cells against syngeneic murine renal cell carcinoma., BJU Int, 95 (3): 421-424, 2005, 2005.02. |
| 268. |
Tsunoda T, Koga H, Yokomizo A, Tatsugami K, Eto M, Inokuchi J, Hirata A, Masuda K, Okumura K,
Naito S:, Inositol 1,4,5-trisphosphate (IP3) receptor type1 (IP3R1) modulates the acquisition of cisplatin resistance in bladder cancer cell lines., Oncogene, 24 (8): 1396-1402, 2005, 2005.02. |
| 269. |
尾本和也、増田克明、平田 晃、江藤正俊、横溝 晃、古賀寛史、内藤誠二：, 診断率向上のための方策 1) 到達法について., 腎泌予防医誌, 13 (1): 14-17, 2005, 2005.01. |
| 270. |
尾本和也、江藤正俊、徳田倫章、立神勝則、原野正彦、内藤誠二、吉満研吾、本田 浩：, Chemical shift MR imaging を用いた腎癌の診断－clear call carcinomaにおける胞体内脂肪検出の試みについて., 西日本泌尿器科, 66 (5): 373-379, 2004, 2004.05. |
| 271. |
立神勝則、江藤正俊、一倉晴彦、尾本和也、原野正彦、古賀寛史、内藤誠二：, マウス腎癌に対する特異的、非特異的免疫の検討., 腎癌研究会会報, 26: 21-22, 2004, 2004.04. |
| 272. |
江藤正俊、横溝 晃、古賀寛史、角田俊之、内藤誠二：, 手術支援ロボット''ZEUS''の腹腔鏡下根治的前立腺摘除術への応用－泌尿器科手術におけるロボット手術の現状と展望－., Japanese Journal of Endourology and ESWL, 17 (2): 140-146, 2004, 2004.02. |
| 273. |
江藤正俊、徳田倫章、原野正彦、尾本和也、田中正利、内藤誠二：, ハンドアシスト法による腹腔鏡下ドナー腎摘出術., Japanese Journal of Endourology and ESWL , 17 (1): 46-21, 2004, 2004.01. |
| 274. |
尾本和也、江藤正俊、内藤誠二：, 腎盂尿管腫瘍に対するハンドアシスト法を用いた後腹膜鏡下腎尿管全摘除術., Japanese Journal of Endourology and ESWL, 17 (1): 21-26, 2004, 2004.01. |
| 275. |
江頭稔久、後藤 健、中村元信、坂本直孝、徳田倫章、阪口 岳、志賀健一郎、宗 裕賢、根岸孝仁、平賀紀行、堀 幹史、結城康平、内野洋志、上領頼之、加野雅子、清島圭二郎、友田稔, 九州大学泌尿器科学教室における1999年から2001年の3年間の臨床統計., 西日泌尿, 65 (9): 565-569, 2003.09. |
| 276. |
Eto M, Bennouna J, Hunter OC, Hershberger PA, Kanto T, Johnson CS, Lotze MT, Amoscato AA., C16 ceramide accumulates following androgen ablation in LNCaP prostate cancer cells., Prostate, 57:66-79, 2003.09. |
| 277. |
江藤正俊、徳田倫章、尾本和也、一倉晴彦、原野正彦、内藤誠二, 進行腎癌に対する Interferon-α、5-fluorouracil、UFT、Leucovorin、Cimetidine 併用療法., 腎癌研究会会報, 24: 7-8, 2003.01. |
| 278. |
Eto M, Hackstein H, Kaneko K, Nomoto K, Thomson AW., Promotion of skin graft tolerance across MHC barriers by mobilization of dendritic cells in donor hemopoietic cell infusions., J. Immunol, 169 (5): 2390-2396, 2002, 2002.09. |
| 279. |
田中正利、北条守文、江藤正俊、野間秀哉、野村博之、山口秋人、内藤誠二, 腎細胞癌に対するハンドアシスト法による腹腔鏡下根治的腎摘除術., 日鏡外会誌, 7 (6): 641-645, 2002.06. |
| 280. |
徳田 倫章、中村 元信、江藤 正俊、一倉 晴彦、中島 信能、古賀 寛史、内藤 誠二、坂本 泰二、上野 光, 腎癌の臨床における血管新生因子群の有用性とVEGF受容体を標的とした遺伝子治療., 西日泌尿, 63 (4): 219-222, 2001
, 2001.04. |
| 281. |
Eto M, Harada M, Tamada K, Tokuda N, Koikawa Y, Nakamura M, Nomoto K, Naito S., Antitumor activity of interleukin-12 against murine bladder cancer., J. Urol, 163 (5): 1549-1552, 2000
, 2000.05. |
| 282. |
Okano S, Eto M, Tomita Y, Yoshizumi T, Yamada H, Minagawa R, Nomoto K, Sugimachi K, Nomoto K., Cyclophosphamide-induced tolerance in rat orthotopic liver transplantation., Transplantation, 71 (3): 447-456, 2001
, 2001.02. |
| 283. |
徳田 倫章、中村 元信、江藤 正俊、内藤 誠二, 腎癌術後の経過観察に血中血管新生因子測定は果たして有用か., 腎癌研究会会報, 19: 25-26, 2000.01. |
| 284. |
徳田倫章、中村元信、江藤正俊、鯉川弥須宏、内藤誠二:, 造影CT上広範なlow density areaを伴う腎細胞癌の臨床的特徴., 腎癌研究会会報, 17: 29-30, 1999, 1999.04. |
| 285. |
分田 裕順、岩坪 暎二、江藤 正俊、井上 幸広、長田 幸夫, カテーテルフリーにできなかった頚髄損傷患者の臨床的検討., 西日泌尿, 61: 684-688, 1999.01. |
| 286. |
Eto M, Kong Y-Y, Uozumi J, Naito S, Nomoto K:, Importance of intrathymic mixed chimerism for the maintenance of skin allograft tolerance across fully allogeneic antigens in mice., Immunology, 96: 440-446, 1999, 1999.03. |
| 287. |
KongY-Y, Eto M, Omoto K, Umesue M, Hashimoto A, Nomoto K, Regulatory T cells in maintenance and reversal of peripheral tolerance in vivo., J Immunol, 157: 5284-5289, 1996.12. |
| 288. |
Omoto K, Y-Y Kong, Nomoto K, Umesue M, Murakami Y, Eto M, Nomoto K, Sensitization of T cell receptor-αβ+ T cells recovered from long-term T cell receptor-downmodulation., Immunology, 88: 230-237, 1996.06. |
| 289. |
Iwatsubo E, Sakamoto Y, Eto M, Kumazawa J, Role of the transversus perinei profundus muscle on voiding: the meaning of UPmax in patients with paralyzed urethral sphincter., Neurourol Urodyn, 15: 169-175, 1996.01. |
| 290. |
Nishimura Y, Eto M, Maeda T, Hiromatsu K, Nomoto K, Y-Y Kong, Nomoto K, The induction of skin xenograft tolerance in rat-to-mouse combination could be affected by DFR mediating cells and antibodies against rat bone marrow cells as well as NK cells in the cyclophosphamide-induced tolerance system., Immunobiol, 193 (5): 420-438, 1995.08. |
| 291. |
Eto M, Nishimura Y, Matsuo K, Omoto K, Goto K, Kumazawa J, Nomoto K, Prolongation of kidney graft survival by cyclophosphamide-induced tolerance in rats., J Urol, 153: 1693-1696, 1995.05. |
| 292. |
Maeda T, Eto M, T Lin, Nishimura Y, Y-Y Kong, Nomoto K, Amelioration of acute graft-versus-host disease and re-establishment of tolerance by short-term treatment with an anti-T cell receptor antibody., J Immunol, 153: 4311-4320, 1994.11. |
| 293. |
Nishimura Y, Eto M, Maeda T, Hiromatsu K, Kobayashi N, Nomoto K, Y-Y Kong, Nomoto K, Inhibition of skin xenograft rejetion by depleting T-cell receptor αβ-bearing cells without T-cell receptor γδ-bearing cells or natural killer cells by monoclonal antibody., Immunology, 83: 196-204, 1994.10. |
| 294. |
Eto M, Nishimura Y, Y-Y Kong, Maeda T, Nomoto K, Kumazawa J, Nomoto K, Importance of intrathymic mixed chimerism for maintenace of skin allograft tolerance aross fully allogeneic (entire major H-2 plus multiminor histocompatibility) antigen barriers in mice., Transplant Proc, 26 (2): 841-844, 1994.04. |
| 295. |
Maeda T, Saikawa I, Hotokebuchi T, Sugioka Y, Eto M, Murakami Y, Nomoto K, Exacerbation of established collagen-induced arthritis in mice treated with an anti-T cell receptor antibody., Arthritis & Rheumatism, 37 (3): 406-413, 1994.03. |
| 296. |
Maeda T, Eto M, Nishimura Y, Y-Y Kong, Nomoto K, Nomoto K, Evidence that donor-specific suppressor T cells can be produced indepently of the thymus., Transplantation, 57 (3): 461-463, 1994.02. |
| 297. |
Eto M, Yoshikai Y, Nishimura Y, Hiromatsu K, Maeda T, Nomoto K, Y-Y Kong, Kubo RT, Kumazawa J, Nomoto K, Inhibition of allograft rejection by anti-T-cell receptor-αβ monoclonal antibodies preserving resistance to bacterial infection., Immunology, 81: 198-204, 1994.02. |
| 298. |
岩坪 暎二、江藤 正俊、分田 裕順、井上 幸広, 外傷性脊髄麻痺., 臨床と研究, 71 (5): 1185-1118, 1994.01. |
| 299. |
岩坪 暎二、江藤 正俊、分田 裕順、井上 幸広, 神経因性膀胱の尿失禁に対する手術療法の試み., 西日泌尿, 56: 449-453, 1994.01. |
| 300. |
江藤 正俊、岩坪 暎二、分田 裕順、井上 幸広、山口 秋人、鷺山 和幸、原 三信, 脊損者の腎尿管結石治療 外科手術とESWLの比較検討., 西日泌尿, 56 (8): 834-838, 1994.01. |
| 301. |
江藤 正俊、岩坪 暎二、分田 裕順、井上 幸広, 脊損者の腎尿管結石治療−外科手術は許されない時代か？−., 日本パラプレジア医学会雑誌, 7 (1): 256-257, 1994.01. |
| 302. |
Maeda T, Eto M, Nishimura Y, Nomoto K, Y-Y Kong, Nomoto K, Role of peripheral hemopoietic chimerism in achieving donor-specific tolerance in adult mice., J Immunol, 150 (3): 753-762, 1993.02. |
| 303. |
山下 博志、玉田 耕治、木元 康介、原岡 正志、熊澤 淨一、岩坪 暎二、井上 幸広、岡田 英一郎、竹原 俊幸、江藤 正俊, 神経因性膀胱のVURに対する膀胱尿管新吻合術., 西日泌尿, 56 (4): 427-431, 1994.01. |
| 304. |
岩坪 暎二、江藤 正俊、分田 裕順、井上 幸広, CICの現状と問題点脊損患者の自己導尿：適応拡大の工夫を中心に., 日本パラプレジア医学会雑誌, 7 (1): 42-43, 1994.01. |
| 305. |
Maeda T, Eto M, Nishimura Y, Nomoto Y, Y-Y Kong, Nomoto K, Direct evidence for clonal destruction of allo-reactive T cells in the mice treated with cyclophosphamide after allo-priming., Immunology, 78: 113-121, 1993.01. |
